Chemistry Books

Book SynopsisThis book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery.Trade Review“This book will be certainly a valuable reference source for all those who are interested in antiviral drug discovery. All of the information contained in this text offers a rich scientific support for researchers in academia and industry at any level who are interested in enhancing their knowledge on a very fascinating scientific topic.” (ChemMedChem, 2012) Table of ContentsChapter 1. HIV life cycle: Targets for anti-HIV agents (Erik De Clercq (Rega Institute)). Chapter 2. PP32 is hot (Duane P. Grandgenett (SLU)). Chapter 3. Integrase mechanism and function (Robert Craigie (NIDDK, NIH)). Chapter 4. Structural studies of retroviral integrases (Mariusz Jaskolski, Jerry N. Alexandratos, Grzegorz Bujacz and Alexander Wlodawer (NIDDK, NCI, NIH)). Chapter 5. Retroviral integration target site selection (Angela Ciuffi and Frederick Bushman (U. Penn)). Chapter 6. The pleiotropic nature of human immunodeficiency virus type 1 integrase mutations (Alan Engelman (Harvard)). Chapter 7. Insights into HIV-1 integrase-DNA interaction (Allison Johnson, Christopse Marchand, and Yves Pommier (NCI, NIH)). Chapter 8. Functional interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase (Thomas Wilkinson and Samson A. Chow (UCLA)). Chapter 9. Cellular cofactors of HIV integration (Wannes Thys, Koen Bartholomeeusen, Zeger Debyser and Jan De Rijck (KULeuven)). Chapter 10. Structural aspects of the lentiviral integrase - LEDGF interaction (Steve Hare, Alan Engelman and Peter Cherepanov (Imperial College London and Harvard)). Chapter 11. Host factors that affect provirus stability and silencing (Richard A. Katz, René Daniel and Anna Marie Skalka (Fox Chase)). Chapter 12. Assays for the evaluation of HIV-1 integrase enzymatic activity, DNA-binding and co-factor interaction (Frauke Christ, Katrien Busschots, Jelle Hendrix, Melissa McNeely, Yves Engelborghs, Zeger Debyser (KU Leuven, Belgium)). Chapter 13. HIV-1 integrase inhibitor design: Overview and historical perspectives (Nouri Neamati (USC)). Chapter 14. HIV integrase inhibitors: from diketoacids to heterocyclic templates: A history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM) leading to the discovery of raltegravir (Melissa S. Egbertson, Neville J. Anthony and Vincenzo Summa). Chapter 15. Elvitegravir, a novel quinolone HIV-1 integrase strand transfer inhibitor (Hisashi Shinkai, Motohide Sato, and Yuji Matsuzaki, Central Pharmaceutical Research Institute, JT Inc., Takatsuki, Japan). Chapter 16. Conformationally constrained tricyclic HIV integrase inhibitors (Maria Fardis, Haolun Jin, Xiaowu Chen, Manuel Tsiang, James Chen, Choung Kim, Matthew Wright (Gilead)). Chapter 17. Slow onset kinetics of HIV integrase inhibitors and proposed molecular model (Edward P. Garvey and Benjamin Schwartz). Chapter 18. Azaindole hydroxamic acids are hiv-1 integrase inhibitors (Michael B. Plewe, Ted W. Johnson). Chapter 19. A simple and accurate in vitro method for predicting serum protein binding of hiv integrase strand transfer inhibitors (Ira B. Dicker, Michael A. Walker, Zeyu Lin, Brian Terry, Lori Pajor, Ming Zheng, B. Narasimhulu Naidu, Jacques Banville, Nicholas A. Meanwell and Mark Krystal (BMS)). Chapter 20. Role of metals in HIV-1 integrase inhibitor design (Mario Sechi, Mauro Carcelli, Dominga Rogolino and Nouri Neamati). Chapter 21. Discovery and development of natural product inhibitors of HIV-1 integrase (Sheo B. Singh (Merck)). Chapter 22. Development of styrylquinoline integrase inhibitors (Jean-Francois Mouscadet, Eric Deprez, Didier Desmaele, Jean d'Angelo (CNRS, France)). Chapter 23. Dicaffeoyltartaric acid and dicaffeoylquinic acid HIV integrase inhibitors (David c. Crosby and W. Edward Robinson, Jr. (UCI)). Chapter 24. Design and discovery of peptide-based inhibitors (Ya-Qiu Long and Nouri Neamati (Shanghai & USC)). Chapter 25. Nucleotide-Based Inhibitors of HIV Integrase (Vasu Nair and Guochen Chi (U. Georgia)). Chapter 26. Design of HIV-1 Integrase Inhibitors Using Computer-aided techniques (Erik Serrao, Rambabu Gundla, Jinxia Deng, Srinivas Odde, Nouri Neamati (USC)). Chapter 27. Application of protein covalent modification to studying the structure and function of HIV-1 integrase and its inhibitors (Xue Zhi Zhao and Terrence R. Burke, Jr.). Chapter 28. HIV-1 intergase-DNA models (Chenzhong Liao, Marc C. Nicklaus (NCI)). Chapter 29. A new paradigm for integrase inhibition: blocking enzyme function without directly targeting the active site (Laith Q. Al-Mawsawi and Nouri Neamati). Chapter 30. Resistance to integrase inhibitors (Leen Hombrouck, Zeger Debyser and Myriam Witvrouw (KU Leuven, Belgium)).

Read more less

Book SynopsisThe complete, hands-on guide to sustainable development Today''s process industries must develop natural resources within an eco-friendly framework that balances current demand with future need. Realizing this goal necessitates global vigilance of three key areaspeople, planet, and prosperityknown as the Triple Bottom Line or, simply, the Triple P. Sustainable Development in the Process Industries details how worldwide implementation of sustainable processes in present-day industries can positively influence the Triple P going forward by lowering poverty, reducing pollution, and conserving resources. This in-depth guide includes: Real-world case studies and examples Individual chapters written by industry experts Application in industries such as petroleum and fuel, food, recycling, mineral processing, and water processing Focus on the micro (molecules, unit operations, processes) to the macTable of ContentsContributors ix Foreword xi Preface xiii 1 Introduction 1 Jan Harmsen 1.1 Reason for This Book, 1 1.2 Scope of the Book, 2 1.3 Use in Education, 2 1.4 Use in Industry, 3 2 Sustainability Metrics, Indicators, and Indices for the Process Industries 5 Joseph B. Powell 2.1 Overview and Scope, 5 2.2 Hierarchy of SD Metrics, Indices, and Indicators, 7 2.3 Practical Tools for the Process Industries, 10 2.4 Summary and Conclusions, 17 References, 19 3 Resource Effi ciency of Chemical Manufacturing Chains: Present and Future 23 Jean-Paul Lange 3.1 Introduction, 23 3.2 Resource Efficiency, 24 3.3 Economic Impact, 32 3.4 Conclusions, 35 References, 35 4 Regional Integration of Processes, Agriculture, and Society 39 Michael Narodoslawsky 4.1 The Formative Character of Raw Materials, 39 4.2 The Systemic Engineering Challenge, 44 4.3 Regional Integration of Technologies, 46 References, 57 5 Eco-industrial Parks in The Netherlands: The Rotterdam Harbor and Industry Complex 59 L. W. Baas and G. Korevaar 5.1 Introduction, 59 5.2 Industrial Ecosystem Programs in Rotterdam, 60 5.3 Conclusions, 76 References, 78 6 By-product Synergy Networks: Driving Innovation Through Waste Reduction and Carbon Mitigation 81 Andrew Mangan and Elsa Olivetti 6.1 Introduction, 81 6.2 BPS Origins, 83 6.3 The BPS Process, 87 6.4 Barriers and Challenges, 94 6.5 Benefi ts and Opportunities, 97 6.6 Examples, 100 6.7 Conclusions, 106 References, 106 7 Fast Pyrolysis of Biomass For Energy and Chemicals: Technologies at Various Scales 109 R. H. Venderbosch and W. Prins 7.1 Introduction, 109 7.2 Oil Properties, 114 7.3 Fast Pyrolysis Process Technologies, 120 7.4 Mass and Energy Balance for Production of Bio-oil and Char in a 2-ton/h Wood Plant, 136 7.5 Bio-oil Fuel Applications, 139 7.6 Chemicals from Bio-oil, 144 7.7 Economics, 148 7.8 Concluding Remarks, 149 References, 150 8 Integrated Corn-Based Biorefi nery: A Study in Sustainable Process Development 157 Carina Maria Alles and Robin Jenkins 8.1 Introduction, 157 8.2 Technology Development for an Integrated Corn-Based Biorefi nery, 159 8.3 LCA Results: ICBR Versus Benchmarks, 165 8.4 Final Refl ections, 168 References, 169 9 Cellulosic Biofuels: A Sustainable Option for Transportation 171 Jean-Paul Lange, Iris Lewandowski, and Paul M. Ayoub 9.1 Introduction, 171 9.2 Case Studies, 175 9.3 Sustainability of Biomass Production, 183 9.4 Conclusions and Recommendations for R&D Activities, 194 Note Added in Proof, 196 References, 196 10 Integrated Urea–Melamine Process at DSM: Sustainable Product Development 199 Tjien T. Tjioe and Johan T. Tinge 10.1 Short Summary of Melamine Development, 199 10.2 Current Uses of Melamine, 200 10.3 Urea Production, 201 10.4 Conventional DSM Stamicarbon Gas-Phase Melamine Production Process, 202 10.5 New Integrated Urea–Melamine Process, 205 10.6 Conclusions, 207 References, 207 11 Sustainable Innovation in the Chemical Industry and Its Commercial Impacts 209 Joseph B. Powell 11.1 Overview, 209 11.2 Historical Perspective, 210 11.3 Innovations in the Age of Sustainability, 212 11.4 Sustainability Driven by Innovation and Performance, 215 References, 216 12 Implementation of Sustainable Strategies in Small and Medium-Sized Enterprises Based on the Concept of Cleaner Production 219 Johannes Fresner and Jan Sage 12.1 Overview, 219 12.2 Active Strategies for Sustainable Management, 220 12.3 Eloxieranstalt A. Heuberger GmbH: Sustainable Management in an Anodizing Plant, 221 12.4 Analysis of the Results, 226 12.5 Implementation of Sustainable Strategies, 230 Appendix: A Successful Regional Cleaner Production Project, 231 References, 236 13 Sustainable Concepts in Metals Recycling and Mineral Processing 237 Nitosh Kumar Brahma 13.1 Overview, 237 13.2 Bioleaching Process Design and Development, 238 13.3 Bioleaching Reactor Design: Applicability of the Core Particle Model, 241 13.4 Industrial Applications, 243 13.5 Conclusions, 245 References, 246 14 Industrial Ecosystem Principles in Industrial Symbiosis: By-product Synergy 249 Qingzhong Wu 14.1 Introduction, 249 14.2 Relationship Between Industrial Symbiosis and Sustainable Development, 250 14.3 Challenges, Barriers, and Countermeasures in Exploration, Evaluation, and Implementation of Industrial Symbiosis, 252 14.4 What By-Product Synergy Is and Is Not, 253 14.5 Work Process and Successful Cases of Industrial Symbiosis, 254 14.6 Conclusions and Recommendations, 261 References, 263 Index 265

Read more less

Book SynopsisChemicals Used for Illegal Purposes helps hazmat professionals and others determine if chemicals at a suspicious site could be used to make illegal substances such as drugs, explosives, pyrotechnics, nerve agents, and other toxins. It profiles dangerous chemicals, covering their appearance, smell, incompatibilities, and identification tests. It features diagrams to assist responders in identifying illegal laboratories. This is a hands-on reference for crime scene responders, policemen, firemen, bomb squad members, drug enforcement officials, and others who need to be able to identify potentially hazardous materials and react quickly and appropriately.Table of ContentsPreface. 1. INTRODUCTION. 2. ALPHABETICAL LIST. 3. MIND-ALTERING DRUGS. Illegal Drugs. Recreational Drugs. 4. PYROTECHNICS. Ammunition. Explosives. Fireworks. Incendiary Devices (Arson). 5. CHEMICAL WEAPONS. Nerve Agents. Vesicants. Blood Agents. Choking Agents. Vomiting Agents. Tear Agents. Toxins. Other Activities Involving Hazardous Chemicals. Recon-Render Safe Ops-Sampling-Take Down/Dismantling. Odors. 6. CONFIRMATION TESTS. GLOSSARY. BIBLIOGRAPHY. CHEMICAL ABSTRACTS SERVICE REGISTRY NUMBERS. INDEX.

Read more less

Book SynopsisThis book examines and evaluates the strategies utilized to design and synthesize pharmaceutically active agents. Significant updates over the last 10 years since the publication of the 1st edition include synthesis of enantiomerically pure isomers, novel chemical methodologies, and new pharmaceutical agents targeted at novel biological endpoints. Written by an experienced successful author, this book meets the needs of a growing community of researchers in pharmaceutical R &D, as well as medical professionals, by providing a useful guide for designing and synthesizing pharmaceutical agents. Additionally, it is a useful text for medicinal chemistry students.Trade Review?In this book, Lednicer presents a detailed discussion of strategies toward the synthesis of pharmaceutical compounds. . . The strength of the book is the wealth of data collected in one relatively short tone?.Table of ContentsPreface 1. PROSTAGLANDINS, PEPTIDOMIMETIC COMPOUNDS, AND RETINOIDS. 1.1 Prostaglandnis. 1.2 Peptidonimetic Compounds. 1.3 Retinoids. 1.4 A Miscellaneous Drug. References. 2. DRUG BASED ON A SUBSTITUTED BENZENE RING 2.1 Arylethanolamines. 2.2 Aryloxypropanolamines. 2.3 Arylsulfonic Acid Derivatives. 2.4 Arylacetic and Arylpropionic Acids. 3. INDENES, NAPHTHALENES AND OTHER POLYCYCLIC AROMATIC COMPOUNDS 3.1 Indenes. 3.2 Naphthalenes. 3.3 Partly Reduced Naphthalenes. 3.4 Tricyclic Compounds. References. 4. STEROIDS; PART 1: ESTRANES, GONANES, AND ANDROSTANES 4.1 Introduction. 4.2 Steroid Starting Materials. 4.3 Estranes. 4.4 Gonanes, the 19-nor Steroids. 4.5 Androstanes. References. 5. STEROIDS; PART 2: COMPOUNDS RELATED TO PROGESTERONE, CORTISONE, AND CHOLESTEROL. 5.1 Introduction. 5.2 Progestins. 5.3 Corticosteroids. 5.4 Compounds Derived from Cholesterol. References. 6. NONSTEROIDAL SEX HORMONES AND THEIR ANTAGONISTS 6.1 Introduction. 6.2 Estrogens. References. 7. OPIOID ANAlGESICS 7.1 Introduction 7.2 Drugs Derived from Morphine. 7.3 Compounds Prepared from Thebaine. 7.4 Morphinans. 7.5 Benzomorphans. 7.6 Analgesics Based on Nonfused Piperidines. References. 8. DRUGS BASED ON FIVE-MEMBERED HETEROCYCLES 8.1 Introduction. 8.2 Rings that Contain One Heteroatom. 8.3 Rings that Contain Two Heteroatoms. 8.4 Rings that Contains Three or More Heteroatoms. References. 9. DRUGS BASED ON SIX-MEMBERED HETEROCYCLES. 9.1 Rings that Contain One Heteroatom. 9.2 Rings that Contain Two Heteroatoms. 9.3 Rings Containing Three Heteroatoms: The Triazines. References. 10. FIVE-MEMBERED HETEROCYCLES FUSED TO A BENZENE RING. 10.1 Compounds that Contain One Heteroatom. 10.2 Compounds that Contain Two Heteroatoms. 10.3 Compounds that Contain Three Heteroatoms. References. 11. SIX-MEMBERED HETEROCYCLES FUSED TO A BENZENE RING 11.1 Compounds that Contain One Heteroatom. 11.2 Compounds that Contain Two Heteroatoms. 11.3 Compounds that Contain Three Heteroatoms. References. 12. SEVEN-MEMBERED HETEROCYCLIC FUSED TO BENZENE. 12.1 Compounds with a Single Heterocyclic Atom. 12.2 Compounds with Two Heteroatoms. References. 13. HETEROCYLES FUSED TO TWO AROMATIC RINGS 13.1 Compounds Containing a Single Heteroatom. 13.2 Compounds Containing Two Heteroatoms. 13.3 Pyridine-Based Fused Tricyclic Compounds. References. 14. BETA LACTAM ANTIBIOTICS 14.1 Penicillins. 14.2 Cephalosporins. 14.3 Monobactams. References. 15. HETEROCYCLES FUSED TO OTHER HETEROCYCLIC RINGS. 15.1 Two Fused Five-Membered Rings. 15.2 Five-Membered Heterocycles Fused to Six-Membered Rings. 15.3 Two Fused Six-Membered Rings. 15.4 Heterodiazepines. 15.5 Heterocyclic Compounds with Three or More Rings. References. Subject Index. Reaction Index. Cross Index of Biological Activities.

Read more less

Book SynopsisPolyolefins is the collective name for polyethylene (PE) and polypropylene (PP) which are amongst the most widely used plastics today, accounting for more than half of total plastics consumption in the developed world. Available for the first time as a two-volume set, Polyolefin Blends and Polyolefin Composites comprehensively summarize and collect many of the technical research accomplishments conducted on blends and composites of polyolefin. The first books to focus exclusively on this subject, they serve as a one stop reference resource for the important research advances and accomplishments in recent years, with major emphasis given to the new area of polyolefin nano-blends and polyolefin nano-composites.

Read more less

Book SynopsisPapers from The American Ceramic Society''s 31st International Conference on Advanced Ceramics and Composites, held in Daytona Beach, Florida, January 21-26, 2007. Content includes papers on recent technical progress by national laboratories, universities and private industries on solid oxide fuel cell technology including SOFC component materials, processing, cell/stack fabrication and design, electrochemical performance and stability, long-term chemical interactions, interface engineering, modeling, test procedures and performance analysis.Table of ContentsPreface xi Introduction xiii Technical Overview 3 Cell and Stack Development/Perfromance 17 Processing/Fabrication 117 Characterization/Testing 129 Electrodes 167 Oxide Conductors 227 Interconnects and Protective Coatings 239 Seals 315 Mechanical Properties 345 Modeling/Simulation 403 Fuel Reforming 425 Author Index 435

Read more less

Book SynopsisThis go-to text provides information and insight into physical inorganic chemistry essential to our understanding of chemical reactions on the molecular level. One of the only books in the field of inorganic physical chemistry with an emphasis on mechanisms, it features contributors at the forefront of research in their particular fields. This essential text discusses the latest developments in a number of topics currently among the most debated and researched in the world of chemistry, related to the future of solar energy, hydrogen energy, biorenewables, catalysis, environment, atmosphere, and human health.Table of ContentsPreface ix Contributors xi 1 Electron Transfer Reactions 1Ophir Snir and Ira A. Weinstock 2 Proton-Coupled Electron Transfer in Hydrogen and Hydride Transfer Reactions 39Shunichi Fukuzumi 3 Oxygen Atom Transfer 75Mahdi M. Abu-Omar 4 Mechanisms of Oxygen Binding and Activation at Transition Metal Centers 109Elena V. Rybak-Akimova 5 Activation of Molecular Hydrogen 189Gregory J. Kubas and Dennis Michael Heinekey 6 Activation of Carbon Dioxide 247 Ferenc Joo 7 Chemistry of Bound Nitrogen Monoxide and Related Redox Species 281Jose A. Olabe 8 Ligand Substitution Dynamics in Metal Complexes 339Thomas W. Swaddle 9 Reactivity of Inorganic Radicals in Aqueous Solution 395David M. Stanbury 10 Organometallic Radicals: Thermodynamics, Kinetics, and Reaction Mechanisms 429Tamas Kegl, George C. Fortman, Manuel Temprado, and Carl D. Hoff 11 Metal-Mediated Carbon--Hydrogen Bond Activation 495Thomas Brent Gunnoe 12 Solar Photochemistry with Transition Metal Compounds Anchored to Semiconductor Surfaces 551Gerald J. Meyer Index 589

Read more less

Book SynopsisMedical accidents account for over 50,000 patient deaths every year in U.S. hospitals alone. Through a wealth of case studies, A Patient Safety Primer for Healthcare Leaders provides examples of how to address the most pressing safety concerns a hospital safety officer may face.Trade Review?This is an easy read, but that does not detract from the useful examples of safety awareness. The two authors make the case that emphasis on promoting safety should be for the benefit of staff as well as patients.? ( Nursing Standard , October 2009)Table of ContentsForeword by Diane C. Pinakiewicz, M.B.A. Acknowledgments. Introduction. Think leadership. Think systems. Think strategy. Think culture. Think behavior. About this book. 1. What Determines Patient Safety? Why make safety happen? What stands in the way of improved healthcare safety? Whose job is it to take the lead? 2. Blueprint for Healthcare Safety Excellence. The working interface: Where exposure to hazard can occur. Healthcare safety-enabling elements. Organizational sustaining systems. Organizational culture. The charge of the safety leader. 3. Nine Dimensions of Organizational Culture. Measuring culture with the Organizational Culture Diagnostic Instrument. Organizational dimensions: The four pillars of culture. Team dimensions. Safety-specific dimensions. Why do some organizations change more readily than others? 4. Qualities of a Great Safety Leader. The Safety Leadership Model. Measuring leadership with the Leadership Diagnostic Instrument (LDI). Personal safety ethic. Leadership style. 5. Leadership Best Practices. Vision. Credibility. Action orientation. Collaboration. Communication. Recognition and feedback. Accountability. Measuring leadership best practices with the LDI. 6. Changing Behavior with Applied Behavior Analysis. What is behavior change? Antecedents, behaviors, and consequences. ABC analysis. Putting the tools to work in your organization. 7. Protecting Your Decision Making from Cognitive Bias. Tragedy on Mount Everest. Cognitive bias and healthcare safety. Biases of data selection. Biases of data use. Case study: Cognitive bias in manufacturing. Putting your cognitive bias knowledge to work. 8. Designing Your Safety Improvement Intervention. The Leading with Safety process. Phase I: The Patient Safety Academy. Step 1: Gain leadership alignment on patient safety as a strategic priority. Step 2: Develop a patient safety vision. Step 3: Perform a current state analysis. Step 4: Develop a high-level intervention plan for phase II. 9. Launching Culture Change for Patient and Employee Safety. Phase II: Achieving safety throughout the organization. Step 5: Engage the organization in the Leading with Safety process. Step 6: Realign systems, both enabling and sustaining. Step 7: Establish a system for behavior observation, feedback, and problem solving. Step 8: Sustain the Leading with Safety process or continual improvement. Case history: Exemplar HealthNet. Leadership Coaching. 10. NASA After Columbia: Lessons for Healthcare. NASA’s approach to culture and climate transformation. Assessing NASA’s existing culture and climate. BST’s NASA intervention. Results at NASA. Lessons for healthcare. Bibliography. Index.

Read more less

Book SynopsisThis series, Advances in Chemical Physics, provides the chemical physics field with a forum for critical, authoritative evaluations of advances in every area of the discipline.Trade Review"This book focuses on an interdisciplinary approach to pharmaceutical problems and does it well." (Journal of the American Chemical Society, March 25, 2009)Table of ContentsTHE SECOND LAW OF NONEQUILIBRIUM THERMODYNAMICS: HOW FAST TIME FLIES (Phil Attard). MULTIPARTICLE COLLISION DYNAMICS: SIMULATION OF COMPLEX SYSTEMS ON MESOSCALES (Raymond Kapral). TWO-PATHWAY EXCITATION AS A COHERENCE SPECTROSCOPY (Tamar Seideman and Robert J. Gordon). TIME-DEPENDENT TRANSITION STATE THEORY (Thomas Bartsch, Jeremy M. Moix, Rigoberto Hernandez, Shinnosuke Kawai, and T. Uzer). ELECTRONIC STRUCTURE REFERENCE CALCULATIONS FOR DESIGNING AND INTERPRETING P AND T VIOLATION EXPERIMENTS (Malaya K. Nayak and Rajat K. Chaudhuri). AUTHOR INDEX. SUBJECT INDEX.

Read more less

Book SynopsisMolecules and Medicine provides, for the first time ever, a completely integrated look at chemistry, biology, drug discovery, and medicine. It delves into the discovery, application, and mode of action of more than one hundred of the most significant molecules in use in modern medicine.Trade Review“Molecules and Medicine is a fascinating introduction to the convergence of chemistry and physiology, and to the emergence of the science of molecular medicine.” (The Nucleus, January 2010) "Molecules and Medicine is extremely well organized and integrates history, chemistry, biology, and pharmacology of drug development seamlessly." (The Quarterly Review of Biology, September 2008) "…I find this to be a useful book for somemone teaching a biochemistry class. Use of examples and information from Molecules and Medicine should make material in lectures seem more relevant to students and assist motivation for learning." (Biochemistry and Molecular Biology Education, May/June 2008) "This is a treasure trove of information about molecules as medicines." (Education in Chemistry, May 2008) "Molecules and Medicine is an engaging book that takes the reader into the world of small molecule clinical therapeutics and how they are discovered and used to improve health." (CHOICE, March 2008) "…numerous colorful illustrations that help to explain the various topics covered make it easy and interesting reading." (ChemBioChem, March 2008)"Dieses Werk schlie?t eine Lucke in der didaktischen Literatur und wird in der Ausbildung von Wissenschaftlern enorm von Nutzen sein." Angewandte Chemie, 2008, 120, 2203-2205Table of ContentsPart I. Introduction 2 Understanding Structural Diagrams of Organic Molecules 4 Some Common Molecules 23 Proteins and Three-Dimensional Protein Structure 26 Some of the Protein Structures That Appear in This Book 32 Part II. Inflammatory, Cardiovascular and Metabolic Diseases Anti-Inflammatory Agents Acetylsalicylic acid (AspirinTM) 38 Naproxen (AleveTM) 39 How Do Anti-Inflammatory Drugs Work? 40 Other Eicosanoids in Inflammation 41 An Overview of Inflammation 42 Celecoxib (CelebrexTM) 43 Prednisone (DeltasoneTM) 44 Methotrexate (TrexallTM) 46 Allopurinol (ZyloprimTM) 47 Antiasthmatic and Antiallergic Agents Salmeterol (SereventTM) 50 Fluticasone Propionate (FloventTM) 51 Montelukast Sodium (SingulairTM) 52 Tiotropium Bromide (SpirivaTM) 53 Loratadine (ClaritinTM) 54 Type 2 Diabetes An Overview of Metabolic Syndrome 56 Antidiabetic and Cholesterol-Lowering Agents Metformin (GlucophageTM) 60 Glipizide (GlucotrolTM) 61 Pioglitazone (ActosTM) 62 Sitagliptin (JanuviaTM) 63 Atorvastatin (LipitorTM) 64 Ezetimibe (ZetiaTM) 65 Cardiovascular Agents Atenolol (TenorminTM) 68 Enalapril (VasotecTM) 69 Candesartan Cilexetil (AtacandTM) 70 Aliskiren (TekturnaTM) 71 Amlodipine (NorvascTM) 72 Nitroglycerin 73 Clopidogrel Bisulfate (PlavixTM) 74 Digoxin (LanoxinTM) 75 Receptors and Signaling Information Flow into the Cell by Chemical Signaling 78 References for Part II 80 Part III. Reproductive Medicine Oral Contraceptives 90 Testosterone 91 Mifepristone (MifeprexTM) 92 Oxytocin (OxytocinTM) 93 Sildenafil (ViagraTM) 94 Osteoporosis Some Aspects of Osteoporosis 96 Alendronate (FosamaxTM) 97 Calcitriol (RocaltrolTM) 98 Raloxifene (EvistaTM) 99 Teriparatide (ForteoTM) 100 Glaucoma and Antiulcer Agents Latanoprost (XalatanTM) 102 Ranitidine (ZantacTM) 103 Omeprazole (PrilosecTM) 104 References for Part III 105 Part IV. Autoimmune Disease and Organ Transplant A Brief Survey of the Immune System 112 Immunosuppressive Agents Azathioprine (ImuranTM) 122 Mycophenolate Mofetil (CeIlCeptTM) 123 Cyclosporin (NeoralTM) 124 Tacrolimus (PrografTM) 125 FTY720 (Fingolimod) 126 Infectious Diseases Antibiotics Amoxicillin (AmoxilTM) 130 Cefaclor (CeclorTM) 132 Doxycycline (VibramycinTM) 133 Azithromycin (ZithromaxTM) 134 Ciprofloxacin (CiproTM) 135 Trimethoprim (TriprimTM) 136 Amikacin (AmikinTM) 137 Vancomycin (VancocinTM) 138 Linezolid (ZyvoxTM) 139 Isoniazid (LaniazidTM) 140 Ancillary Antibiotics 142 Drug Resistance 143 Antiviral Agents On Viruses and Viral Diseases 146 Acyclovir (ZoviraxTM) 148 Ribavirin (VirazoleTM) 149 Oseltamivir (TamifluTM) 150 Zidovudine (Retrovir, AZTTM) 151 Zalcitabine (HividTM) 152 Nevirapine (ViramuneTM) 153 Efavirenz (SustivaTM) 154 Lopinavir + Ritonavir (KaletraTM) 155 UK427857 (Maraviroc) 156 Antifungal Agents Amphotericin (FungizoneTM) 160 Fluconazole (DiflucanTM) 161 Caspofungin (CancidasTM) 162 Terbinafine (LamisilTM) 163 Antimalarial and Antiparasitic Agents Parasitic Diseases: A Focus on Malaria 166 Chloroquine (ArdenTM) 167 Artemether + Lumefantrine (CoArtemTM) 168 Atovaquone + Proguanil (MalaroneTM) 169 Miltefosine (I mpavidoTM) 170 Nitazoxanide (AliniaTM) 171 Ivermectin (StromectolTM) 172 References for Part IV 173 Part V. Malignant Disease An Overview of Cancer 184 Capecitabine (XelodaTM) 187 Carboplatin (ParaplatinTM) 188 Vinblastine (VelbanTM) 189 Paclitaxel (TaxolTM) 190 Cyclophosphamide (CytoxanTM) 191 Tamoxifen (NolvadexTM) 192 Irinotecan (CamptosarTM) 193 Bleomycin (BlenoxaneTM) 194 Imatinib (GleevecTM) 195 Sunitinib (SutentTM) 196 Bortezomib (VelcadeTM) 197 Ancillary Anticancer Agents 198 References for Part V 200 Part VI. Drugs Acting on the Nervous System Pain and Analgesia Lidocaine (XylocaineTM) 208 Morphine (AvinzaTM) 209 Acetaminophen (Tylenol TM) 210 Fentanyl (DuragesicTM) 211 Sodium Thiopental (Sodium PentothalTM) 212 Gabapentin (NeurontinTM) 213 Diazepam (ValiumTM) 214 Sumatriptan (ImitrexTM) 215 Hypnotics (Insomnia) and Antismoking Zolpidem (AmbienTM) 218 Ramelteon (RozeremTM) 219 Varenicline (ChantixTM) 220 The Brain, Neurotransmission and Molecular Neurotransmitters 221 Neurodegenerative and Psychiatric Diseases Levodopa (LarodopaTM) 224 Donepezil (AriceptTM) 225 Antiepileptic Agents 226 Antianxiety Agents 228 Antidepressants 229 Antipsychotics 232 References for Part VI 233 Glossary 237 Index 249

Read more less

Book SynopsisPhysical Properties of Macromolecules integrates years of detailed research in physical properties of polymers with more traditional ?classroom topics.Trade Review"This resource serves as the ideal companion for government laboratories, industrial research scientists, engineers and professionals in polymer science fields who are interested in fully grasping all aspects of physical polymer science". (ET Polymers, 8 January 2011) Table of ContentsPreface. Part One Glass Transitions in Amorphous Polymers. 1. Glass Transitions in Amorphous Polymers: Basic Concepts. 2. Diffusion in Amorphous Polymers Near the Glass Transition Temperature. 3. Lattice Theories for Polymer–Small-Molecule Mixtures and the Conformational Entropy Description of the Glass Transition Temperature. 4. dc Electric Field Effects on First- and Second-Order Phase Transitions in Pure Materials and Binary Mixtures. 5. Order Parameters for Glasses: Pressure and Compositional Dependence of the Glass Transition Temperature. 6. Macromolecule–Metal Complexes: Ligand Field Stabilization and Glass Transition Temperature Enhancement. Part Two Semicrystalline Polymers and Melting Transitions. 7. Basic Concepts and Molecular Optical Anisotropy in Semicrystalline Polymers. 8. Crystallization Kinetics via Spherulitic Growth. 9. Experimental Analysis of Semicrystalline Polymers. Part Three Mechanical Properties of Linear and Crosslinked Polymers. 10. Mechanical Properties of Viscoelastic Materials: Basic Concepts in Linear Viscoelasticity. 11. Nonlinear Stress Relaxation in Macromolecule–Metal Complexes. 12. Kinetic Analysis of Molecular Weight Distribution Functions in Linear Polymers. 13. Gaussian Statistics of Linear Chain Molecules and Crosslinked Elastomers. 14. Classical and Statistical Thermodynamics of Rubber-Like Materials. Part Four Solid State Dynamics of Polymeric Materials. 15. Molecular Dynamics via Magnetic Resonance, Viscoelastic, and Dielectric Relaxation Phenomena. 16. Magnetic Spin Diffusion at the Nanoscale in Multiphase Polymers and Molecular Complexes. Index. Postface.

Read more less

Book SynopsisThe all-encompassing guide to total quality process control for injection molding In the same simple, easy-to-understand language that marked the first edition, Total Quality Process Control for Injection Molding, Second Edition lays out a successful plan for producing superior plastic parts using high-quality controls. This updated edition is the first of its kind to zero in on every phase of the injection molding process, the most commonly used plastics manufacturing method, with an all-inclusive strategy for excellence. Beginning with sales and marketing, then moving forward to cover finance, purchasing, design, tooling, manufacturing, assembly, decorating, and shipping, the book thoroughly covers each stage to illustrate how elevated standards across individual departments relate to result in the creation of a top-notch product. This Second Edition: Details ways to improve plastic part design and quality Includes material and proTrade Review"In this lengthy book, a total quality approach for injection moulding applications is presented . . . hence, the book provides practical assistance for operators that have to produce proper parts without delay and defaults. In addition, the book gives a good introduction for quality managers to set up a TQM approach within their company." (Materials Views, 2 June 2011) "In the same simple, easy-to-understand language that marked the first edition, Total Quality Process Control for Injection Molding, Second Edition lays out a successful plan for producing superior plastic parts using high-quality controls". (Daily Finance, 14 December 2010) Table of ContentsPreface. 1. Total Quality Process Control. ISO 9001. Documentation. Establishing Process Ownership. Ideas and Methods. 2. Implementing Total Quality Process Control (TQPC). Quality Improvement Plan. Statistical Process Control (SPC). Controlling the Process. Cp the Control of Operations. Cpk-Centered Process Control. Establishing Company Quality Objectives. Customer Quality. 3. Managing for Success, Commitment to Quality. Objectives for Managing a Quality System. Proactive Preventive Action. Total Quality Process Control. Principles for Quality Systems Engineering. Objectives for Managing a Quality System. Customer-Supplier Quality Agreements. Product Quality Determination. Form, Fit, and Function (FFF). Product Requirements. Existing Mold Considerations. Establishment of Responsibility. Department TQPC Responsibility. Estimated Piece Part Price. Multifunctionality. Assembly and Decorating. Manufacturing Capability. Computer-Integrated Manufacture (CIM). Tracking Manufacture. RFID. EDI. Control of Operations. Process Control. Control Charting. International Organization for Standardization (ISO) Accreditation. Program Monitoring—Communication. Communicating Quality in Business. Communications. Surveys. Quality Function Deployment (QFD). QFD in Operation. Customer Feedback. Critical to Quality (CTQ). Building on TQPC, Product Manufacture. Checklists. Quality Circles. Fishbone Analysis. Failure Mode and Effects Analysis. Types of FMEAs. FMEA Timing. Implementing an FMEA. FMEA Development. 4. Customer Satisfaction. Manufacturing and Supplier Input. Vendor Selection. Vendor Survey. Customer and Supplier Agreements. Vendor Clinics. Product Requirements. Product Preproduction Review. 5. Organization Responsibilities. Quality Operations. Quality Uniformity. Compliance Audits. Six Sigma Introduction. Procedure. Quality Problems. TQPC Management Operations. Preventive Action. 6. Establishing the Limits for Quality Control. Preproduction Product Analysis. Taguchi Methods. Prototyping. Mold Limits. Material Selection. Calculation of Plastic Part Cost. Case Study of Product Cost Analysis. Estimating Part Cycle Time. Mold Part Cavity Estimation. Mold Size Considerations. Injection Molding Machine Selection. Melt Generation. Molding Machine Screw-type Considerations. Machine Hourly Rate. Machine Setup Charges. Calculating Product Manufacturing Cost. Material Supplier Limits. Establishing Manufacturing Limits. Auxiliary Equipment. In-Process Inspection. Establishing Total Quality Process Control. Acceptable Quality Limits. 7. Material Selection and Handling. Thermosets. Thermoplastics. Classifying the Polymers. Product Certifi cation. Material Specifi cation. Product Variable Specification. Incoming Material Testing. Material Testing Equipment. Material Safety Data Sheets. Record Accuracy. Bar Coding: An Aid in Total Quality Process Control. Regrind Control. Material Handling and Storage. Regrind Usage. Processing Aids. 8. The Mold. Computer-Integrated Manufacture. Pre-mold Design Checklist. Tooling. Selecting Materials for the Mold. Cavity Selection. Runner Systems. Cavity Runner Layout. Runner System Design. Gating the Part. Sprues and Nozzles. Parting Lines. Side Core Pulls. Core Selection. Part Ejection. Venting the Cavity. Core Venting. Positive Cavity Venting. Temperature Control. Cooling Systems. Mold Connection Types. Cooling Time. Mold Shrinkage. Hot-Runner Molds. Mold Maintenance. 9. Manufacturing Equipment. Machinery Selection. Process Control. Electric Injection Molding Machines. Injection Molding Machine Nomenclature and Operation. Reciprocating Screw Injection Molding Machine. The Injection Molding Machine. Selecting Barrel Heater Conditions. Pyrometer. Thermocouples. Mold Fit and Support. Machine and Mold Clamping Systems. Vented-Barrel Machines. Maintenance of Machinery. 10. Auxiliary Equipment. Material Feeders and Blenders. Automatic System. Central Systems. Material Feed to the Injection Molding Machine. Material Blending at the Hopper. Blending Quality Checks. Color Concentrate Blending. Regrind Usage. Material Drying. Plant Equipment Cooling Systems. Granulators or Grinders. Part Removal, Conveyor Systems, and Robots. Quality Inspection Equipment. Quick Mold Change. 11. Processing. Production Startup for Process Control. Acceptable Quality Level Limits. Networking Production. The Injection Molding Process. Injection Molding Startup. Other Molding Variables. Fine Tuning the Cycle. Regrind Effects on Part Quality. Determining the Missing Variable. Process Control Charting. Maintaining Process Control. Quality Maintenance. Solutions to Typical Molding Problems. Controlling and Monitoring Process Variables. Process Line Integration. 12. Part Testing at the Machine. Selecting the Test. Verifying Molding Conditions. Destructive Tests. Nondestructive Tests. Testing of Plated Parts. Post-Mold Shrinkage Testing. Conditioned Parts. 13. Part Handling and Packaging. Planning. Part Removal. Part Handling and Packaging. Automatic Part Packaging. Robots. 14. Part Design Influence. Selecting the Correct Design Parameters. Material Selection. Part Design for End-Use Applications. Threads. Undercuts. Inserts. Insert Loading. Integral Hinges. 15. Assembly Techniques. Plan for Assembly. Automated Assembly. Automated Inspection. Assembly Techniques. 16. Decorating Considerations. Control of the Process. Decorating Techniques. Surface Preparation. Molded Colors. Surface Finish. Painting. Spray and Wipe. Two-Shot Molding. In-Mold Decorating. Vacuum Metallizing. Electroplating. Flocking. Gravure Decorating. 17. Customer and Employee Satisfaction. Quality Awareness. Appendix A. Quality Management System (QMS) Control of Documents Procedure. Appendix B. Design of Experiments (DOE): Statistical Troubleshooting Process Screening for Reducing the Number of Variables. Appendix C. Checklists. Appendix D. Supplier Evaluation Survey. Appendix E. Mold Problem Solutions. Appendix F. Decoration & Information Solutions. Glossary. Bibliography. Index.

Read more less

Book SynopsisThe serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug''s cardiac safety profile a high priority during both development and post-approval monitoring.Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug''s life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, government officials, and students.Trade Review“This fills the void for a book addressing the safety issues, especially cardiac safety issues, of therapeutic agents in development. The content is high yield, easy to understand and succinct, covering the multiple steps involved in the drug safety and approval process.” (Doody's, April 2009)Table of ContentsForeword. Preface. Acknowledgments. Abbreviations. Part I: INTRODUCTION. 1. The Importance of Cardiac Safety Assessments. 2. The Biological Basis of Adverse Drug Reactions. Part II: CARDIAC FUNCTION AND PATHOLOGY. 3. Cardiac Structure and Function. 4. Cardiac Pathophysiology and Disease. SECTION III: DRUG DISCOVERY AND NONCLINICAL DEVELOPMENT. 5. Drug Discovery and Drug Design. 6. Nonclinical Development. SECTION IV: PREAPPROVAL CLINICAL DEVELOPMENT. 7. The Thorough QT/QTc Trial. 8. General Safety Assessments. SECTION V: POSTMARKETING ASSESSMENT METHODOLOGIES. 9. Therapeutic Use Trials and Meta-analyses. 10. Assessment Methodologies in Nonexperimental Postmarketing Surveillance. 11. Postmarketing Proarrythmic Cardiac Safety Assessments. 12. Generalized Cardiac Safety. SECTION VI: BEHAVIORAL DRUG SAFETY. 13. Medication Errors, Adherence, and Concordance. SECTION VII: INTEGRATIVE DISCUSSION. 14. Future Directions in Drug Safety. References. Index.

Read more less

Book SynopsisThe first book to discuss how nanoparticles can be used in biotechnological applications such as biomedical diagnostics and environmental analyses. Discusses novel applications of force measurements as a tool for medical diagnostics and fluorescent colloidal particles as detection tools in biotechnological systems.Table of ContentsAbout the Editor vii Preface ix Contributors xi 1. Reactive Nanocolloids for Nanotechnologies and Microsystems 1 Christian Pichot 2. Nanoparticles Comprising pH/Temperature-Responsive Amphiphilic Block Copolymers and Their Applications in Biotechnology 31 Peihong Ni 3. Evolution in Malaria Disease Detection: From Parasite Visualization to Colloidal-Based Rapid Diagnostic 65 Duangporn Polpanich, Pramuan Tangboriboonrat, and Abdelhamid Elaissari 4. Antigen-Antibody Interactions Detected by Quasi-Elastic Light Scattering and Electrophoretic Mobility Measurements – A New Concept for Latex Immunodiagnostic Test 95 Teresa Basinska and Stanislaw Slomkowski 5. Biospecific Reactions by Affinity Latexes from Diagnostics to Multiplex Assay 117 Haruma Kawaguchi 6. Fluorescent Colloidal Particles as Detection Tools in Biotechnology Systems 133 Igor Nabiev, Alyona Sukhanova, Mikhail Artemyev, and Vladimir Oleinikov 7. Biofunctionalized Magnetic Micro/Nanoparticles for Biosensing Technologies 169 Nicole Jaffrezic-Renault, Claude Martelet, Yann Chevolot, and Jean-Pierre Cloarec 8. Colloids, Biotechnology, and Microfluidics 199 Cecile Cottin-Bizonne and Rosaria Ferrigno 9. Gas Sensors Based on Ultrathin Films of Conducting Polymers and Nanocomposites 223 Manoj K. Ram, Ozlem Yavuz, and Matt Aldissi 10. Force Measurements between Emulsion Droplets As a New Tool for Medical Diagnostics 247 Abdelhamid Elaissari, Celine Genty, and Olivier Mondain-Monval 11. Particles for Protein Analysis in Microfluidic Systems 275 Anne Le Nel, Myriam Taverna, and Jean-Louis Viovy 12. Semicarbazide/a-oxo Aldehyde Site-Specific Ligation Chemistry: From Peptide Microarrays to the Micropatterning of Polycarbonate or Titanium Oxide Using Silica Nanoparticles 299 Ouafaa El-Mahdi, Vianney Souplet, Olivier Carion, Clement Roux, Jean-Michel Garcia, Celine Maillet, Christophe Olivier, Oleg Melnyk and Jean-Olivier Durand 13. Electrical Detection of Antibodies from Human Serum Based on the Insertion of Gold-Labeled Secondary Antibodies into Microor Nanogaps 329 Lionel Marcon, Didier Stie´venard, and Oleg Melnyk Index 353

Read more less

Book SynopsisThe book addresses the basics, applications, and manufacturing of plasmid biopharmaceuticals. The survey of the most relevant characteristics of plasmids provides the basics for designing plasmid products (applications) and processes (manufacturing). Key features that the authors include in the book are: i) consistency and clear line of direction, ii) an extensive use of cross-referencing between the individual chapters, iii) a rational integration of chapters, iv) appellative figures, tables and schemes, and v) an updated, but selected choice of references, with a focus on key papers.Trade Review"While very technical and written for practitioners in the field, the writing is direct, and extensive references and a detailed list of abbreviations is included." (Book News, 1 October 2011) Table of ContentsPreface. Acknowledgment. Abbreviations. Part I Basics. 1 Historical Perspective. 2 Gene Transfer with Plasmid Biopharmaceuticals. 3 Product and Process Development. 4 Structure. 5 Analytical Characterization. 6 Delivery. Part II Applications. 7 Ethical and Safety Issues. 8 Human and Veterinary Markets. 9 Human Case Studies: Pandemic Infl uenza and Critical Limb Ischemia. 10 Veterinary Case Studies: West Nile, Infectious Hematopoietic Necrosis, and Melanoma. Part III Manufacturing. 11 Good Manufacturing Practice and Validation. 12 Product Specifi cations and Quality Control. 13 Cell Culture. 14 An Overview of Downstream Processing. 15 Primary Isolation. 16 Intermediate Recovery. 17 Final Purifi cation. 18 Process Synthesis. Part IV Concluding Remarks and Outlook. 19 Concluding Remarks and Outlook. Index.

Read more less

Book SynopsisThis book helps pharmaceutical and medical researchers better understand, design, and manage clinical trials through its industry-specific viewpoint that shows how adaptive research technology and methods benefit the drug industry.Trade Review"This book certainly brings the relevant issues upfront." (Chemistry & Industry, June 2010) "It is ideal for senior executives who want a strategic view of adaptive methods, managers looking for practical opportunities to significantly improve the efficiency of their operations, and statisticians interested in learning the broader ramifications of their arcane expertise." (Journal of Clinical Research Best Practices, April 2010) "Rosenberg captures the current excitement surrounding adaptive clinical research, and provides a very readable introduction to the methodologies involved in implementing such research." (Journal for Clinical Studies, March 2010)Table of ContentsPreface. Acknowledgments. 1 Opportunity for Efficiency. The Adaptive Solution. An Industrial Success Story. Signs of Trouble Ahead. Converging Challenges. The Struggle to Replace Lost Revenues. Clinical Research is the Key. Behind the High Costs of Clinical Development. High Costs and Increasing Prices. Growing Pressures Mandate Greater Efficiency. The High Risk of Current Development Practices. Economic Consequences of Faster Clinical Development. Thriving in a New Era. References. 2 Defining and Extending the Adaptive Approach. The Adaptive Concept. Knowledge, Time and Decision-Making. The Value of Early Knowledge. The Spectrum of Design and Operational Adaptations. Maximizing the Adaptive Approach: Agile Clinical Development. Measure Performance in Real-time. Metrics in Action. Right Information to the Right Eyes at the Right Time. Make Timely Decisions. Organize Work in Lean Processes. Rework in Clinical Studies. Backflow of Patient Data. Match Technology with Tasks. Objections to Adaptive Methods. Integrity and Validity. The Regulatory Environment. The Complexity of Clinical Research. Conclusion. References. 3 Design Adaptations Part One: Finding the Right Dose. Background. Types of Design Adaptations. Order of Discussion. Dosing Nomenclature. Determining Maximum Safe Dose. Single Arm. Continual Reassessment Method. Other Bayesian Dose-Finding Methods. Determining Optimal Dose (Pruning). Multiple Arms. Improvements over Conventional Approaches to Dose Finding. Dose Selection in Practice. Optimizing Dose Selection. Minimizing Costs versus Maximizing Information. Surrogate Endpoints. Conclusion. References. 4 Design Adaptations Part Two: Additional Design Changes. Sample-Size Reestimation. The Trouble with Planning Estimates. The High Cost of "Underbuilt" Studies. The Benefits of Reestimation and Rightsizing. Reestimation and Trial Stages. Rules to Restrict Reestimation. Adjusting Sample Size for Nuisance Parameters. Seamless Designs: Combining Multiple Phases. When to Consider Seamless Studies. Seamless Phase I/Phase II Trials. Seamless Phase II/Phase III Trials. Planning Issues in Seamless Trials. Phase I-II-III Designs. Adaptive Randomization. Response-Adaptive Randomization. Other Forms of Adaptive Randomization. Other Types of Design Adaptations. Noninferiority-to-Superiority Design. Adaptive Hypotheses and Subpopulations. Treatment Switching. Conclusions. References. 5 Operational Adaptations. Design and Operational Adaptations. The Nature and Significance of Operational Adaptations. Implementing Operational Adaptations. Enrollment and Other Site Issues. Data Quality. Monitoring. Site Closeout and Database Lock. Supporting Functions for Efficient Operations. The Bottom Line. References. 6 Agile Clinical Development. Benefits of Agile Development. A Development Example. Program Planning. Safety Testing (Phase I). Design. Planning. Operational Considerations. Putting the Plan into Action. Benefits Realized. Transition to Dose-Finding Study. Dose Finding (Phase II). Design. Planning. Operational Considerations. Putting the Plan into Action. Benefits Realized. Transition to Confirmatory Studies. Confirmatory Testing (Phase III). Design. Planning. Operational. Putting the Plan into Action. Benefits Realized. Transition to Regulatory Filings. Summing Up: The Power of Agile Development. 7 Planning Adaptive Programs. Determining Design Adaptations and their Requirements. Determining Operational Requirements to Support Design Adaptations. Ensuring the Ability to Meet Operational Requirements. The Importance of Programmatic Thinking. Looking Ahead. Advisory and Oversight Groups. Optimizing the Planning Process. Regulatory Discussions. Contingency Planning. Planning Tools and Techniques. Decision Trees. Simulation. Uncertainties in Clinical Research. Simulation Tools. Simulation Step by Step. The Limitations of Simulation. Conclusions. References. Sources of Simulation Software. 8 Statistics and Decision Making in Adaptive Research. The Frequentist Approach. What Frequentist Results Say about the Results of a Clinical Study. Using Frequentist Results to Make Decisions Based on Individual Trials. Other Issues with Frequentist Methods. The Bayesian Approach. Prior Distributions. How Bayesian Statistics Works. Bayesian Statistics in the Real World. Bayesian Methods in Clinical Research. Comparing Bayesian and Frequentist Methods. Prior Distributions. The Pharma Context. Learning and Confirming. Ethical and Operational Issues. Regulatory Considerations. Conclusions. Frequentists, Bayesians, and Pragmatists. References. 9 The Agile Platform. Essential Types of Data. Management Cycles in Clinical Studies. The Common Platform for Design and Operational Adaptations. Data Capture. Data-Capture Technologies. The First Generation. The Second Generation. The Third Generation. Data Cleaning and Validation Technology. Data Analysis Tools. Randomization. Site Management. Supply-Chain Management. Communications. Conclusions. References. 10 The Future of Clinical Development. Is Restructuring an Alternative to Improving Clinical Development? Greater Efficiency: Changes that Everyone Can Applaud. Biotechs and Emerging Low-Cost Competitors. Globalization, Offshoring, and Outsourcing. Managing More Complex Trials. Individualized Medicine Demands Greater Efficiency. A More Important Role for Postmarketing Studies. The Reward for Greater Efficiency. Financial Implications of the Agile Approach. Financial Implications of the Agile Approach for the Drug Industry. A Brighter Future for Clinical Development. First Steps toward Agile Development. An Eight-Point Program for Embracing the Adaptive Approach. References. Index.

Read more less

Book SynopsisHighlighting international approaches; the book details strategies to minimize contamination, residue monitoring programs, and classes of drugs and chemicals that pose contaminant risk in livestock. Focuses attention on drug and chemical residues in edible animal products Covers novel computational, statistical, and mathematical strategies for dealing with chemical exposures in food animals Details major drug classes used in food animal production and their residue risks Highlights efforts at harmonizing and the differences among areas like US, EU, Canada, Australia, South America, China, and Asia, where the issue of chemical exposures has significant impact on livestock products Ties veterinary clinical practice and the use of these drugs in food animals with regulatory standards and mitigation practices Trade Review“This book is an excellent resource for those interested in an overview of drug residue issues across multiple species.” (Journal of the American Veterinary Medical Association, 15 March 2015) Table of ContentsPreface vii Contributors ix 1 Importance of Veterinary Drug Residues 1 Ronald E. Baynes and Jim E. Riviere 2 Pharmacokinetic Principles for Understanding Drug Depletion as a Basis for Determination ofWithdrawal Periods for Animal Drugs 9 Sanja Modric 3 Evaluation of Drug Residue Depletion in the Edible Products of Food-Producing Animals forEstablishing Withdrawal Periods and Milk Discard Times 35 Dong Yan 4 Establishing Maximum Residue Limits in Europe 49 Kornelia Grein and Isaura Duarte 5 Methods to Derive Withdrawal Periods in the European Union 65 G. Johan Schefferlie and Stefan Scheid 6 Population Pharmacokinetic Modeling to Predict Withdrawal Times 81 Sharon E. Mason 7 Physiologically Based Pharmacokinetic Modeling 95 Jennifer Buur 8 Residue Avoidance in Beef Cattle Production Systems 115 Virginia Fajt and Dee Griffin 9 Residue Avoidance in Dairy Cattle Production Systems 137 Geof Smith 10 Residue Avoidance in Aquaculture Production Systems 161 Renate Reimschuessel 11 Residue Avoidance in Small Ruminant Production Systems 193 Kevin Anderson and Reha Azizoglu 12 Residue Avoidance in Swine Production Systems 221 Ronald E. Baynes and Glen Almond 13 Confirmatory Methods for Veterinary Drugs and Chemical Contaminants in Livestock Commodities233 Hui li 14 The Food Animal Residue Avoidance Databank: An Example of Risk Management of VeterinaryDrug Residues 289 Thomas W. Vickroy, Ronald E. Baynes, Lisa Tell and Jim E. Riviere 15 Risk Management of Chemical Contaminants in Livestock 303 Ronald E. Baynes and Jim E. Riviere Index 313

Read more less

Book Synopsis Delivers comprehensive coverage of key subjects in self-assembly and nanotechnology, approaching these and related topics with one unified concept. Designed for students and professionals alike, it explores a variety of materials and situations in which the importance of self-assembly nanotechnology is growing tremendously. Provides clear schematic illustrations to represent the mainstream principles behind each topic. Table of ContentsPreface and Acknowledgments. PART I. SELF-ASSEMBLY. 1. UNIFIED APPROACH TO SELF-ASSEMBLY. 1.1. Self-Assembly through Force Balance. 1.2. General Scheme for the Formation of Self-Assembled Aggregates. 1.3. General Scheme for Self-Assembly Process. 1.4. Concluding Remarks. References. 2. INTERMOLECULAR AND COLLOIDAL FORCES. 2.1. Van der Waals Force. 2.2. Electrostatic Force: Electric Double-Layer. 2.3. Steric and Depletion Forces. 2.4. Solvation and Hydration Forces. 2.5. Hydrophobic Effect. 2.6. Hydrogen Bond. References. 3. MOLECULAR SELF-ASSEMBLY IN SOLUTION I: MICELLES. 3.1. Surfactants and Micelles. 3.2. Physical Properties of Micelles. 3.3. Thermodynamics of Micellization. 3.4. Micellization versus General Scheme of Self-Assembly. 3.5. Multicomponent Micelles. 3.6. Micellar Solubilization. 3.7. Applications of Surfactants and Micelles. References. 4. MOLECULAR SELF-ASSEMBLY IN SOLUTION II: BILAYERS, LIQUID CRYSTALS, AND EMULSIONS. 4.1. Bilayers. 4.2. Vesicles, Liposomes, and Niosomes. 4.3. Liquid Crystals. 4.4. Emulsions. References. 5. COLLOIDAL SELF-ASSEMBLY. 5.1. Forces Induced by Colloidal Phenomena. 5.2. Force Balance for Colloidal Self-Assembly. 5.3. General Scheme for Colloidal Self-Assembly. 5.4. Micelle-like Colloidal Self-Assembly: Packing Geometry. 5.5. Summary. References. 6. SELF-ASSEMBLY AT INTERFACES. 6.1. General Scheme for Interfacial Self-Assembly. 6.2. Control of Intermolecular Forces at Interfaces. 6.3. Self-Assembly at the Gas–Liquid Interface. 6.4. Self-Assembly at the Liquid–Solid Interface. 6.5. Self-Assembly at the Liquid–Liquid Interface. 6.6. Self-Assembly at the Gas–Solid Interface. 6.7. Interface-Induced Chiral Self-Assembly. References. 7. BIO-MIMETIC SELF-ASSEMBLY. 7.1. General Picture of Bio-mimetic Self-Assembly. 7.2. Force Balance Scheme for Bio-mimetic Self-Assembly. 7.3. Origin of Morphological Chirality and Diversity. 7.4. Symmetric Bio-mimetic Self-Assembled Aggregates. 7.5. Gels: Networked Bio-mimetic Self-Assembled Aggregates. 7.6. Properties of Bio-mimetic Self-Assembled Aggregates. 7.7. Future Issues. References. PART II. NANOTECHNOLOGY. 8. IMPLICATIONS OF SELF-ASSEMBLY FOR NANOTECHNOLOGY. 8.1. General Concepts and Approach to Nanotechnology. 8.2. Self-Assembly and Nanotechnology Share the Same Building Units. 8.3. Self-Assembly and Nanotechnology Are Governed by the Same Forces. 8.4. Self-Assembly versus Manipulation for the Construction of Nanostructures. 8.5. Self-Aggregates and Nanotechnology Share the Same General Assembly Principles. 8.6. Concluding Remarks. References. 9. NANOSTRUCTURED MATERIALS. 9.1. What Are Nanostructured Materials? 9.2. Intermolecular Forces During the Formation of Nanostructured Materials. 9.3. Sol–Gel Chemistry. 9.4. General Self-Assembly Schemes for the Formation of Nanostructured Materials. 9.5. Micro-, Meso-, and Macroporous Materials. 9.6. Mesostructured and Mesoporous Materials. 9.7. Organic–Inorganic Hybrid Mesostructured and Mesoporous Materials. 9.8. Microporous and Macroporous Materials. 9.9. Applications of Nanostructured and Nanoporous Materials. 9.10. Summary and Future Issues. References. 10. NANOPARTICLES: METALS, SEMICONDUCTORS, AND OXIDES. 10.1. What are Nanoparticles? 10.2. Intermolecular Forces During the Synthesis of Nanoparticles. 10.3. Synthesis of Nanoparticles. 10.4. Properties of Nanoparticles. 10.5. Applications of Nanoparticles. 10.6. Summary and Future Issues. References. 11. NANOSTRUCTURED FILMS. 11.1. What Is Nanostructured Film? 11.2. General Scheme for Nanostructured Films. 11.3. Preparation and Structural Control of Nanostructured Films. 11.4. Properties and Applications of Nanostructured Films. 11.5. Summary and Future Issues. References. 12. NANOASSEMBLY BY EXTERNAL FORCES. 12.1. Force Balance and the General Scheme of Self-Assembly Under External Forces. 12.2. Colloidal Self-Assembly Under External Forces. 12.3. Molecular Self-Assembly Under External Forces. 12.4. Applications of Colloidal Aggregates. 12.5. Summary and Future Issues. References. 13. NANOFABRICATION. 13.1. Self-Assembly and Nanofabrication. 13.2. Unit Fabrications. 13.3. Nanointegrated Systems. 13.4. Summary and Future Issues. References. 14. NANODEVICES AND NANOMACHINES. 14.1. General Scheme of Nanodevices. 14.2. Nanocomponents: Building Units for Nanodevices. 14.3. Three Element Motions: Force Balance at Work. 14.4. Unit Operations. 14.5. Nanodevices: Fabricated Nanocomponents to Operate. 14.7. Summary and Future Issues. References. Index.

Read more less

Book SynopsisReviews the role of peripheral receptor mechanisms in the transduction of pain. This title provides a framework for the development of effective rationally-designed analgesic drugs and therapies with and promoting basic and clinical studies on potentially interesting peripheral receptor targets.Table of ContentsFOREWORD by Lars Arendt-Nielsen. PREFACE. CONTRIBUTORS. PART I PERIPHERAL MECHANISM IN CLINICAL PAIN CONDITIONS. 1. Role of Peripheral Mechanisms in Craniofacial Pain Conditions (Barry J. Sessle). 2. Role of Peripheral Mechanisms in Spinal Pain Conditions (Brian E. Cairns and Pradit Prateepavanich). PART II SPECIFIC RECEPTOR TARGETS FOR PERIPHERAL ANALGESICS. 3. Voltage-Gated Sodium Channels in Peripheral Nociceptive Neurons as Targets For the Treatment of Pain (Theodore R. Cummins). 4. Potassium Channels (Daisuke Nishizawa1, Toru Kobayashi, and Kazutaka Ikeda). 5. Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain (Joe McGivern). 6. Adenosine Receptors (Jana Sawynok). 7. Acid-Sensing Ion Channels and Pain (Roxanne Y. Walder, Christopher J. Benson and Kathleen A. Sluka). 8. Vanilloid (TRPV1) and Other Transient Receptor Potential Channels (Marcello Trevisani and Arpad Szallasi). 9. Glutamate Receptors (Brian E. Cairns). 10. Serotonin Receptors (Malin Ernberg). 11. Adrenergic Receptors (Antti Pertovaara). 12. Cholinergic Receptors and Botulinum Toxin (Parisa Gazerani). 13. Cannabinoids and Pain Control in the Periphery (Jason J. McDougall). 14. Opioid Receptors (Claudia Herrera Tambeli, Luana Fischer and Carlos Amilcar Parada). 15. Calcitonin Gene-Related Peptide and Substance P (Ranjinidevi Ambalavanar and Dean Dessem). 16. Role of Somatostatin and Somatostatin Receptors in Pain (Ujendra Kumar). 17. Cytokines (Tumor Necrosis Factor, Interleukins) and Prostaglandins (Per Alstergren). 18. Neurotrophic Factors and Pain (Peter Svensson). PART III DELIVERY SYSTEMS. 19. Topical and Systemic Drug Delivery Systems Targeted Drug Therapy (Urs Hafeli and Amit Kale). 20. Gene Therapy for Pain (Marina Mata and David J. Fink). 21. Topical Analgesics (Akhlaq Waheed Hakim and Brian E. Cairns). Index.

Read more less

Book SynopsisVolume 9 in a scientific research series, covering macromoleculesThis book, Macromolecules Containing Metal and Metal-like Elements, presents research developments in the study of: supramolecular chemistry, supramolecular architecture and supramolecular self-assemblies. The topics addressed involve materials containing metals and metal-like elements as well as the possible applications of hybrid materials. The volume offers a broad series of coverage with conclusions and perspectives for the various areas covered.Trade Review"The strength of the book lies in the breadth of the coverage in terms of both the variety of areas and the rigor of how each area is treated. The book is suitable for a wide audience and will serve as an important addition to the library of anyone that seeks to be at the forefront of the area." (Zentralblatt Math, 2010)Table of ContentsPreface xvii Series Preface xxi 1. Supramolecular Structures and Functions with Inorganic Building Blocks 1 Katsuhiko Ariga, Ajayan Vinu, Jonathan P. Hill, Pavuluri Srinivasu, Somobrata Acharya, and Qingmin Ji I. Introduction 2 II. Hybrid Lipid Thin Films 2 III. Layer-by-Layer Assemblies 8 IV. Structure Transcription 13 V. Functional Mesoporous Hybrids 20 VI. Future Perspectives 30 VII. Acknowledgments 30 VIII. References 30 2. Self-Assembly of Hydrophilic Polyoxometalate Macroanions in Dilute Solutions 35 Melissa L. Kistler, Joe Pigga, and Tianbo Liu I. Introduction 36 II. Solution Behavior of POM Macroions: Soluble but Still Aggregate 38 III. Characterization of the Supramolecular Structures 40 IV. Controlling the Blackberry Formation and Blackberry Size by Changing Solvent Quality 41 V. Counterion Association around Discrete POM Macroions 45 VI. Counterion Condensation around Blackberries 46 VII. Identification of the Driving Forces Responsible for the Blackberry Formation 47 VIII. Soft Nature of the Blackberries—Effect of Additional Hydrogen Bonding 47 IX. Weak Electrolyte Type POMs 48 X. Effect of Additional Electrolytes 49 XI. Kinetic Process of Blackberry Formation 52 XII. Cation Transport over the Anionic Blackberry Membrane 55 XIII. Macroions in Solution: An important Linkage among Simple Ions, Polymers, Colloids, and Biosystems 57 XIV. Conclusions 58 XV. Acknowledgments 58 XVI. References 58 3. Supramolecular Structures and Polyoxometalates 61 Samar K. Das I. Introduction 62 II. Supramolecular Features of Polyoxometalate-Supported Transition-Metal Complexes 62 III. Polyoxometalate Crown Ether Complexes with Supramolecular cations 91 IV. Supramolecular Water Clusters Associated with Polyoxometalates 103 V. Concluding Remarks 118 VI. Acknowledgements 119 VII. References 120 4. Supramolecular Coordination Networks Employing Sulfonate and Phosphonate Linkers: From Layers to Open Structures 125 George K. H. Shimizu, Jared M. Taylor, and Ramanathan Vaidhyanathan I. Introduction 126 II. The Sulfonate Group as a Ligand 127 III. Layered Metal Sulfonates 128 IV. Nonlayered Metal Sulfonates 137 A. Dynamic and Crystalline Metal Sulfonate Frameworks 147 B. Hydrogen Bonded Second Sphere Coordination Networks 155 V. Metal phosphonates 167 VI. Conclusion 176 VII. References 177 5. Transition-Metal-Based Linear Chain Compounds 181 Moumita Majumdar, and Jitendra K. Bera I. Introduction 182 II. Ligand-Supported Metal Chains 183 A. Linear Chains of Chromium 183 B. Linear Metal Chains of Cobalt 187 C. Linear Chains of Copper 197 D. Linear Chains of Nickel 200 E. Linear Chains of Palladium 211 III. Unsupported Metal Chains 221 A. Linear Chain Compounds of Rhodium 221 B. Linear Chain of Iridium 233 C. The Platinum Blues 241 IV. Concluding Remarks 246 V. References 247 6. Boronate-Linked Materials: Ranging from Amorphous Assemblies to Highly Structured Networks 255 Brett M. Rambo, R. William Tilford, Laura M. Lanni, Jie Liu, and John J. Lavigne I. Introduction and Scope 256 II. Supramolecular Boronate Assemblies 257 A. ‘‘Traditional’’ Hydrogen Bonded Supramolecular Assemblies 258 B. ‘‘Novel’’ Phenyl-Boron-Phenyl Sandwich Supramolecular Assembly 258 C. Coordination-Based Macrocyclic Assemblies 261 D. Coordination-Based Linear Assemblies 267 III. Covalently Linked Boronate Assemblies 270 A. Covalently Linked Macrocyclic and Cage Assemblies 271 B. Covalently Linked Linear Assemblies 279 C. Covalently Linked Network Assemblies 284 IV. Summary and Outlook 289 V. References 291 7. Mixed-Metal Supramolecular Complexes Coupling Polyazine Light Absorbers and Reactive Metal Centers 295 Shamindri M. Arachchige, and Karen J. Brewer I. Introduction 299 A. Light Absorption 300 i. Molecular Photovoltaics 301 ii. Ruthenium Charge Transfer Light Absorbers 301 iii. Osmium Charge Transfer Light Absorbers 303 B. Solar Water Splitting 304 C. Metal Complexes as DNA Targeting Agents 306 D. Supramolecular Charge Transfer Complexes 306 E. Cyclic Voltammetry of Charge Transfer Light Absorbers 308 II. Supramolecular Complexes Coupling Ru(II) or Os(II) Polyazine Light Absorbers and Rh(III) Reactive Metal Centers 309 A. The Complexes [(bpy)2Ru(BL)RhH2(PPh3)2]3+ 309 i. Redox Properties of [(bpy)2Ru(BL)RhH2(PPh3)2]3+ 309 ii. Spectroscopic Properties of [(bpy)2Ru(BL)RhH2(PPh3)2]3+ 311 iii. Photophysical and Photochemical Properties of [(bpy)2Ru(BL)RhH2(PPh3)2]3+ 311 B. Cyanide-Bridged Ru(II)-Rh(III) Complexes 312 i. Redox Properties of Cyanide-Bridged Ru(II)-Rh(III) Complexes 312 ii. Spectroscopic Properties of Cyanide-Bridged Ru(II)-Rh(III) Complexes 313 iii. Photophysical and Photochemical Properties of Cyanide-Bridged Ru(II)-Rh(III) Complexes 313 C. Polyazine-Bridged [(bpy)2Ru(dpp)Rh(bPy)25+ 314 i. Redox Properties of [(bpy)2Ru(dpp)Rh(bPy)25+ 314 ii. Spectroscopic Properties of [(bpy)2Ru(dpp)Rh(bpy)25+ 314 iii. Photophysical and Photochemical Properties of [(bpy)2Ru(dpp)Rh(bpy)25+ 315 D. Tridentate-Bridged Complexes: [(ttpy)Ru(tpy-(Ph)n-tpy)Rh(ttpy)]5+ (n = 0−2) 315 i. Redox Properties of [(ttpy)Ru(tpy-(Ph)n-tpy)Rh(ttpy)]5+ 316 ii. Spectroscopic Properties of [(ttpy)Ru(tpy-(Ph)n-tpy)Rh(ttpy)]5+ 317 iii. Photophysical and Photochemical Properties of [(ttpy)Ru(tpy-(Ph)n-tpy)Rh(ttpy)]5+ 317 E. Ru(II)-Rh(III) Complexes Bridged with a Flexible Spacer: [(Me2phen)2Ru(Mebpy-CH2-CH2-Mebpy)Rh(Me 2bpy)2]5+ 319 i. Redox Properties of [(Me2phen)2Ru(Mebpy-CH2-CH2-Mebpy)Rh(Me2bpy)2]5+ 320 ii. Spectroscopic Properties of [(Me2phen)2Ru(Mebpy-CH2-CH2-Mebpy)Rh(Me2bpy)2]5+ 320 iii. Photochemical and Photophysical Properties of [(Me2phen)2Ru(Mebpy-CH2-CH2-Mebpy)Rh(Me2bpy)2 ]5+ 321 F. Dendrimeric Ru(II)/Os(II)-Rh(III) Complexes: [M{(dpp)Rh(ppy)2}3](PF6)5 321 i. Redox Properties of [M{(dpp)Rh(ppy)2}3](PF6)5 322 ii. Spectroscopic Properties of [M{(dpp) Rh(ppy)2}3](PF6)5 323 iii. Photophysical and Photochemical Properties of [M{(dpp)Rh(ppy)2}3](PF6)5 323 G. Extended Supramolecular Architectures with Fe(II)/Ru(II)/Rh(III) 324 H. Stereochemically Defined Tridentate-Bridged Ru(II)-Rh(III) Complex 324 i. Redox Properties of [(tpy)Ru(tppz)RhCl3](PF6)2 325 ii. Spectroscopic Properties of [(tpy)Ru(tppz)RhCl3](PF6)2 326 iii. Photophysical and Photochemical Properties of [(tpy)Ru(tppz)RhCl3](PF6)2 326 I. Photoinitiated Electron Collection 327 i. LA-BL-Rh-BL-LA Supramolecular Assemblies 328 ii. Redox Properties of LA-BL-Rh-BL-LA 328 iii. Spectroscopic Properties of LA-BL-Rh-BL-LA 330 iv. Photochemical and Photophysical Properties of LA-BL-Rh-BL-LA 331 v. Photoinitiated Electron Collection on a Rhodium Center 332 vi. Photochemistry with LA-BL-Rh-BL-LA Architectures 333 III. Supramolecular Complexes Coupling Ru(II) or Os(II) Polyazine Light Absorbers to Reactive Pt(II) Metal Centers 338 A. Cyanide-Bridged Ru(II)-Pt(II) Complexes: [(bpy)2(CN)Ru(CN)Pt(dien)](ClO4)2 and [(dien)Pt(NC)(bpy)2 Ru(CN)Pt(dien)](ClO4)4 338 i. Redox Properties of [(bpy)2(CN)Ru(CN)Pt(dien)](ClO4)2 and [(dien)Pt(NC)(bpy)2Ru(CN)Pt(dien)](ClO4)4 338 ii. Spectroscopic Properties of [(bpy)2(CN)Ru(CN)Pt(dien)](ClO4)2 and [(dien)Pt(NC)(bpy)2 Ru(CN)Pt(dien)](ClO4)4 339 iii. Photochemical and Photophysical Properties of [(bpy)2(CN)Ru(CN)Pt(dien)](ClO4)2 and [(dien)Pt(NC)(bpy)2Ru(CN)Pt(dien)](ClO4)4 339 B. A Ru(II)-Pt(II) Complex as a Chemodosimeter 340 C. Ru(II)-Pt(II) Complexes Bridged by Flexible Spacers 341 i. Redox Properties of [(bpy)2Ru(Mebpy-CH2-CH2-Mebpy)PtCl2](PF6)2 341 ii. Spectroscopic Properties of [(bpy)2Ru(Mebpy-CH2-CH2-Mebpy)PtCl2](PF6)2 341 D. A bpm-Bridged Ru(II)-Pt(II) Complex: [(bpy)2Ru(bpm)PtCl2]2+ 342 i. Redox Properties of [(bpy)2Ru(bpm)PtCl2]2+ 342 ii. Spectroscopic Properties of [(bpy)2Ru(bpm)PtCl2]2+ 343 E. Ru(II)-Pt(II) dpp-Bridged Complexes: [(bpy)2Ru(dpp)PtMe2]2+ and [(bpy)2Ru(dpp)PtCl2]2+ 343 i. Redox Properties of [(bpy)2Ru(dpp)PtMe2]2+ and [(bpy)2Ru(dpp)PtCl2]2+ 343 ii. Spectroscopic Properties of [(bpy)2Ru(dpp)PtMe2]2+ and [(bpy)2Ru(dpp)PtCl2]2+ 344 iii. Photophysical and Photochemical Properties of [(bpy)2Ru(dpp)PtMe2]2+ and [(bpy)2Ru(dpp)PtCl2]2+ 344 F. Ru(II)-Pt(II) Complexes Bridged by a BL Ligand with Two Inequivalent Sites 345 i. Redox Properties of [(bpy)2Ru(AB)PtCl2](PF6)2 and [(bpy)2Ru(BA)PtCl2](PF6)2 345 ii. Spectroscopic Properties of [(bpy)2Ru(AB)PtCl2](PF6)2 and [(bpy)2Ru(BA)PtCl2](PF6)2 346 iii. Photophysical and Photochemical Properties of [(bpy)2Ru(AB)PtCl2](PF6)2 and [(bpy)2 Ru(BA)PtCl2 ](PF6)2 346 G. DNA Binding of the Ru(II)-Pt(II) Complex: [(tpy)Ru(dtdeg)PtCl]Cl3 347 H. Ru(II)-Pt(II) Complexes with Amino Linkages: [(bpy)2Ru(BL)PtCl2](PF6)2(BL = bpy(CONH(CH2)3NH2)2 and phenNHCO(COOHbpy)) 347 i. Photophysical Properties and DNA Binding Ability of [(bpy)2Ru(BL)PtCl2](PF6)2 348 ii. Photophysical Properties and Photocatalytic Activity of [(bpy)2Ru(BL)PtCl2](PF6)2 348 I. Systematic Studies of Ru(II)/Os(II)-Pt(II) Complexes with Polyazine Bridging Ligands 349 i. Redox Properties [(bpy)2M(BL)PtCl2](PF6)2 349 ii. Spectroscopic Properties of [(bpy)2M(BL)PtCl2](PF6)2 351 iii. DNA Binding by [(bpy)2M(dpb)PtCl2](PF6)2 353 J. Dendrimeric Ru(II)-Pt(II) Complexes Bridged by Polyazine Bridging Ligands 354 i. Redox and Spectroscopic Properties of [Ru{(dpq) (PtCl2)}3](PF6)2 354 ii. Multifunctional DNA Binding and Photocleavage Agent: [{(bpy)2Ru(dpp)}2Ru(dpp)PtCl2](PF6)6 355 IV. Supramolecular Complexes Coupling Ru(II) Polyazine Light Absorbers to Reactive Pd(II) Metal Centers 356 A. Ru(II)-Pd(II) Complexes Bridged by dpp and bpm Ligands: [(bpy)2Ru(dpp)PdCl2](PF6)2 and [(bpy)2 Ru(bpm)PdCl2](ClO4)2 356 i. Redox Properties of [(bpy)2Ru(dpp)PdCl2](PF6)2 and [(bpy)2 Ru(bpm)PdCl2](ClO4)2 356 ii. Spectroscopic Properties of [(bpy)2Ru(dpp)PdCl2](PF6)2 and [(bpy)2Ru(bpm)PdCl2](ClO4)2 356 B. Ru(II)-Pd(II) Complexes Bridged by an Extended Polyazine Ligand: [(tBu2bpy)2Ru(tpphz)PdCl2](PF6)2 357 i. Spectroscopic Properties of [(tBu2bpy)2Ru(tpphz)PdCl2](PF6)2 358 C. Ru(II)-Pd(II) Complexes Bridged by bpm type Ligands: [(bpy)2Ru(BL)PdMeCl]2+ 358 D. A Ru(II)-Pd(II) Complex Bridged by a Flexible Polyazine Bridging Ligand: [(bpy)2Ru(DMB)PdCl2]2+ 359 i. Redox and Spectroscopic Properties of (bpy)2Ru(DMB)PdCl2]2+ 359 ii. Photochemistry of [(bpy)2Ru(DMB)PdCl2]2+ 359 V. Conclusions 364 VI. Acknowledgments 366 VII. References 366 8. Supramolecular Hybrid Materials—Integrating Functionality with Sensing 369 Ramo´n Martı´nez-Ma´n˜ez, Fe´lix Sanceno´n, Ana Bele´n Descalzo, and Knut Rurack I. Introduction 370 II. Enhanced Coordination by Preorganization. Surface Chelate Effect and Signaling 371 III. Enhanced Signaling by Preorganization 378 IV. Assembly-Disassembly 381 V. Selectivity by Polarity and Size. Biomimetic Signaling 386 VI. Switching, Gating and Signaling 391 VII. Conclusions 399 VIII. Acknowledgments 400 IX. References 400 9. Molecular Recognition Process between Nucleobases and Metal-Oxalato Frameworks 407 Oscar Castillo, Antonio Luque, Juan P. Garcıá-Tera´n, and Pilar Amo-Ochoa I. Introduction 408 A. Molecular Recognition 408 B. Nucleobases 409 C. Oxalate 412 II. Metal-Oxalato-Nucleobase Extended Systems 413 III. Other metal-nucleobase 1D Extended Systems 427 VI. Hybrid Systems Based on Metal-Oxalato and Protonated Nucleobases 433 V. Conclusions 443 VI. References 443 10. Crystal Engineering of Coordination Polymers 451 Marius Andruh, and Catalina Ruiz-Pe´rez I. Introduction 452 II. Synthetic Approaches 453 A. The Node-and-Spacer Paradigm 454 i. Bridging ligands 455 ii. Oligonuclear Complexes as Nodes 461 a. Alkoxo-Bridged Binuclear Copper(II) Complexes as Nodes 463 b. Homobinuclear Complexes with Compartmental Ligands as Nodes 468 c. Heterobinuclear Complexes as Node 473 d. Heterotrimetallic Coordination Polymers 478 B. Flexible Ligand Approach: Polycarboxylates as Anionic Linkers. A Case Study—Malonato Complexes 479 i. Dicarboxylates 480 ii. The Case of Malonate. 482 iii. Influence of the synthetic conditions 482 iv. The use of co-ligands 489 v. Ligand Adaptation 493 vi. Perspectives 497 C. The Building-Block Approach 497 i. Oxalato-Bridged Coordination Ploymers 498 ii. Bisoxamidato Complexes as Building Blocks 501 iii. Cyano-Bridged Coordination Polymers 501 III. Conclusions and Perspectives 505 IV. Acknowledgments 506 V. References 506 Index 513

Read more less

Book SynopsisThis series provides the chemical physics field with a forum for critical, authoritative evaluations of advances in every area of the discipline.Trade Review"This volume continues the standard of excellent set by it predecessors. It is an essential item for any modern university or research institution library." (Journal of the American Chemical Society, September 24, 2008)Table of ContentsRecent Advances in the Field of Integral Equation Theories: Bridge Functions and Applications to Classical Fluids (Jean-Marc Bomont). The Chemical Environment of Ionic Liquids: Links Between Liquid Structure, Dynamics, and Solvation (Mark N. Kobrak) Counterion Condensation in Nucleic Acid (Alex Spasic and Udayan Mohanty). Physiochemical Applications of Scanning Electrochemical Microscopy (Francois O. Laforge, Peng Sun, and Michael V. Mirkin). The vx-H Line Shapes of Centrosymmetric Cyclic Dimers Involving Weak Hydrogen Bonds (Oliver Henri-Rousseau and Pal Blaise). Time-Resolved Photoelectron Spectroscopy of Nonadiabatic Dynamics in Polyatomic Molecules (Albert Stolow and Jonathan G. Underwood). Author Index. Subject Index.

Read more less

Book SynopsisOrganic Reactions is a collection of chapters, each devoted to a single reaction or a definitive phase of a reaction of wide applicability, with particular attention given to limitations, interfering influences, effects of structure, and the selection of experimental techniques. Volume 70 includes two chapters, the first takes a look at the Catalytic Asymmetric Strecker Reaction, the second at the Synthesis of Phenols and Quinones via Fischer Carbene Complexes. Includes tables that contain all possible examples of the reactions under consideration Each reaction is fully referenced to the primary literature Table of Contents1. THE CATALYTIC ASYMMETRIC STRECKER REACTION (Masakatsu Shibasaki, Motomu Kanai, and Tsuyoshi Mita). 2. THE SYNTHESIS OF PHENOLS AND QUINONES VIA FISCHER CARBENE COMPLEXES (Marcey L. Waters and William D. Wulff ). CUMULATIVE CHAPTER TITLES BY VOLUME. AUTHOR INDEX, VOLUMES 1-70. CHAPTER AND TOPIC INDEX, VOLUMES 1-70.

Read more less

Book SynopsisWith chapters provided by international leading experts, this book covers the recent advances in protein and peptide mass spectrometry.Trade Review"This book will be a valuable reference as it contains plenty of depth and substance to be of interest to experienced practitioners of mass spectrometry and related techniques, but is still accessible to pharmaceutical researchers who want to learn more about MS technologies and its applications." (American Society for Mass Spectrometry, 1 July 2012) Table of ContentsPREFACE xv CONTRIBUTORS xvii PART I METHODOLOGY 1 1 Ionization Methods in Protein Mass Spectrometry 3 Ismael Cotte-Rodriguez, Yun Zhang, Zhixin Miao, and Hao Chen 1.1 History of the Development of Protein Mass Spectrometry 4 1.2 Laser-Based Ionization Methods for Proteins 5 1.3 Spray-Based Ionization Methods for Proteins 13 1.4 Ambient Ionization Methods 20 1.5 Conclusions 30 Acknowledgments 30 References 30 2 Ion Activation and Mass Analysis in Protein Mass Spectrometry 43 Cheng Lin and Peter O’Connor 2.1 Introduction 43 2.2 Ion Activation and Tandem MS Analysis 46 2.3 Mass Analyzers 59 References 81 3 Target Proteins: Bottom-up and Top-down Proteomics 89 Michael Boyne and Ron Bose 3.1 Mass Spectral Approaches to Targeted Protein Identification 89 3.2 Bottom-up Proteomics 90 3.3 Top-down Approaches 96 3.4 Next-Generation Approaches 98 References 99 4 Quantitative Proteomics by Mass Spectrometry 101 Jacob Galan, Anton Iliuk, and W. Andy Tao 4.1 Introduction 101 4.2 In-Cell Labeling 105 4.3 Quantitation via Isotopic Labeling of Proteins 107 4.4 Quantitation via Isotopic Labeling on Peptides 112 4.5 Label-Free Quantitation 116 4.6 Conclusions 119 Acknowledgment 120 References 120 5 Comparative Proteomics by Direct Tissue Analysis Using Imaging Mass Spectrometry 129 Michelle L. Reyzer and Richard M. Caprioli 5.1 Introduction 129 5.2 Conventional Comparative Proteomics 130 5.3 Comparative Proteomics Using Imaging MS 131 5.4 Conclusions 136 Acknowledgments 137 References 137 6 Peptide and Protein Analysis Using Ion Mobility–Mass Spectrometry 139 Jeffrey R. Enders, Michal Kliman, Sevugarajan Sundarapandian, and John A. McLean 6.1 Ion Mobility–Mass Spectrometry: Instrumentation and Separation Selectivity 139 6.2 Characterizing and Interpreting Peptide and Protein Structures 147 6.3 Applications of IM-MS to Peptide and Protein Characterizations 152 6.4 Future Directions 158 Acknowledgments 159 References 160 7 Chemical Footprinting for Determining Protein Properties and Interactions 175 Sandra A. Kerfoot and Michael L. Gross 7.1 Introduction to Hydrogen–Deuterium Exchange 175 7.2 Experimental Procedures 178 7.3 Mass Spectrometry-Based HDX in Practice 182 7.4 Protein Footprinting via Free-Radical Oxidation 193 7.5 Chemical Crosslinking 198 7.6 Selective and Irreversible Chemical Modification 201 7.7 Conclusion 205 References 206 8 Microwave Technology to Accelerate Protein Analysis 213 Urooj A. Mirza, Birendra N. Pramanik, and Ajay K. Bose 8.1 Introduction 213 8.2 Microwave Technology 215 8.3 Summary 224 Acknowledgments 224 References 224 9 Bioinformatics and Database Searching 231 Surendra Dasari and David L. Tabb 9.1 Overview 231 9.2 Introduction to Tandem Mass Spectrometry 231 9.3 Overview of Peptide Identification with Database Searching 234 9.4 MyriMatch-IDPicker Protein Identification Pipeline 235 9.5 Results of a Shotgun Proteomics Study 246 9.6 Improvements to MyriMatch Database Search Engine 248 9.7 Applications of MyriMatch-IDPicker Pipeline 250 9.8 Conclusions 251 Acknowledgments 251 References 251 PART II Applications 253 10 Mass Spectrometry-Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery 255 Christine L. Andrews, Michael R. Ziebell, Elliott Nickbarg, and Xianshu Yang 10.1 Introduction 255 10.2 Affinity Selection Mass Spectrometry (AS-MS) 256 10.3 Solution-Based AS-MS as Screening Technologies 258 10.4 Gas-Phase Interactions 267 10.5 Enzyme Activity Assays Using MS for Screening or Confirming Drug Candidates 271 10.6 Conclusions and Future Directions 276 References 277 11 Utilization of Mass Spectrometry for the Structural Characterization of Biopharmaceutical Protein Products 287 Amareth Lim and Catherine A. Srebalus Barnes 11.1 Introduction 287 11.2 MS-Based Approach for the Characterization of Recombinant Therapeutic Proteins 288 11.3 Cell Culture Development 290 11.4 Purification Development 294 11.5 Formulation Development 300 11.6 Analytical Method Development 304 11.7 Confirmation of Structure/Product Comparability Assessment 311 11.8 Conclusions 313 Acknowledgments 315 References 315 12 Post-translationally Modified Proteins: Glycosylation, Phosphorylation, and Disulfide Bond Formation 321 Anthony Tsarbopoulos and Fotini N. Bazoti 12.1 Introduction 321 12.2 Glycosylation 322 12.3 Phosphorylation 338 12.4 Disulfide Bond Detection and Mapping 347 12.5 Future Perspectives 350 Acknowledgments 352 Abbreviations 353 References 354 13 Mass Spectrometry of Antigenic Peptides 371 Henry Rohrs 13.1 Introduction 371 13.2 Analysis of Antigenic Peptides 374 13.3 Examples of the Application of Mass Spectrometry to Antigenic Peptide Study 381 13.4 Future Work 385 Acknowledgments 386 Abbreviations 387 References 387 14 Neuropeptidomics 393 Jonathan V. Sweedler, Fang Xie, and Adriana Bora 14.1 Introduction 393 14.2 Neuropeptidomics: Characterizing Peptides in the Brain 394 14.3 Sample Preparation for Mass Spectrometry 395 14.4 Separations 405 14.5 Peptide Characterization via Mass Spectrometry 407 14.6 Conclusions 419 14.7 Future Perspectives 419 Acknowledgments 420 References 420 15 Mass Spectrometry for the Study of Peptide Drug Metabolism 435 Patrick J. Rudewicz 15.1 Introduction 435 15.2 Peptide Drug Metabolism 436 15.3 LC-MS/MS for Metabolite Identification 437 15.4 Quantitative Analysis 439 15.5 Case Study: IL-1b Protease Inhibitors 440 15.6 Future Directions 445 References 445 INDEX 449

Read more less

Book SynopsisThe first such book devoted exclusively to the MQED theory of long-range intermolecular forces, this resource gives the first presentation of the second quantized Maxwell field formulation of the theory. The coverage includes recently developed non-perturbative approaches for treating a variety of intermolecular interactions.Table of ContentsPREFACE. 1 MOLECULAR QUANTUM ELECTRODYNAMICS: BASIC THEORY. 1.1 Background. 1.2 Quantum Description of Matter. 1.3 Electrodynamics and Maxwell Equations. 1.4 Quantization of the Free Electromagnetic Field. 1.5 Interacting Particle–Radiation Field System. 1.6 Multipolar Lagrangian. 1.7 Multipolar Hamiltonian. 1.8 Canonical Transformation. 1.9 Perturbation Theory Solution. 1.10 State Sequence Diagrams. 2 MOLECULAR QUANTUM ELECTRODYNAMICS: FIELD THEORETIC TREATMENT. 2.1 Introduction. 2.2 Nonrelativistic Quantum Field Theory. 2.3 Quantum Canonical Transformation. 2.4 Multipolar Maxwell Fields. 2.5 Minimal-Coupling Maxwell Fields. 2.6 Multipolar Maxwell Fields in the Vicinity of a Source. 2.7 Higher Multipole Moment Maxwell Fields. 2.8 Maxwell Fields of a Diamagnetic Source. 2.9 Electromagnetic Energy Density. 2.10 Poynting’s Theorem and Poynting Vector. 3 INTERMOLECULAR FORCES. 3.1 Concept of Intermolecular Potential. 3.2 Short-Range Forces. 3.3 Long-Range Forces. 3.4 Electrostatic Interaction. 3.5 Induction Forces. 3.6 Dispersion Forces. 4 RESONANT TRANSFER OF ENERGY. 4.1 Introduction. 4.2 Diagrammatic Perturbation Theory. 4.3 State Sequence Diagram Representation. 4.4 Energy Transfer Between Chiral Systems. 4.5 Emitter–Absorber Model. 4.6 Response Theory Calculation. 4.7 Time-Dependent Energy Transfer and Causality. 4.8 Proof of Causality of Energy Transfer to all Orders in Perturbation Theory. 5 RETARDED DISPERSION FORCES. 5.1 Introduction. 5.2 Casimir–Polder Potential: Perturbation Theory. 5.3 Near-Zone Potential: London Dispersion Energy. 5.4 Far-Zone Dispersion Potential. 5.5 State Sequence Diagrams for Dispersion Force. 5.6 Dispersion Interaction Between One Ground and One Excited Molecule: Perturbation Theory. 5.7 Response Theory Calculation of Dispersion Forces. 5.8 Dispersion Potential via the Method of Induced Multipole Moments. 5.9 Discriminatory Dispersion Interactions. 5.10 Interactions Involving Magnetically Susceptible Molecules. 5.11 Measurements of Casimir Effect. 6 MANY-BODY FORCES. 6.1 Introduction. 6.2 Axilrod-Teller-Muto Dispersion Energy Shift. 6.3 Retarded Triple-Dipole Dispersion Potential: Perturbation Theory. 6.4 Triple-Dipole Dispersion Energy Shift via Craig–Power Hamiltonian. 6.5 Triple-Dipole Dispersion Potential via Correlations of the Dressed Vacuum Field. 6.6 N-Body Dispersion Potential. 6.7 Four-Body Retarded Dispersion Potential. 6.8 Three-Body Dispersion Interaction Involving One Excited Molecule. 6.9 Mediation of Resonance Energy Transfer by a Third Body. 7 INTERMOLECULAR INTERACTIONS IN A RADIATION FIELD. 7.1 Introduction. 7.2 Radiation-Induced Dispersion Force: Perturbation Theory. 7.3 Dynamic Mechanism. 7.4 Static Mechanism. 7.5 Molecular and Pair Orientational Averaging. 7.6 Polarization Analysis. 7.7 Collapsed Graphs and Effective Interaction Hamiltonian. 7.8 Radiation-Induced Intermolecular Interaction via the Method of Induced Moments. 7.9 Discriminatory Intermolecular Interaction in a Radiation Field: Perturbation Theory. 7.10 Radiation-Induced Chiral Discrimination: Induced Moment Method. 7.11 Freely Tumbling Chiral Pair in the Presence of Circularly Polarized Light. 7.12 Radiation-Induced Intermolecular Energy Shifts Involving Magnetic Dipole and Electric Quadrupole Polarizable Molecules. 7.13 Higher Order Radiation-Induced Discriminatory Intermolecular Interaction. APPENDIX A Higher Multipole-Dependent Second-Order Maxwell Field Operators. APPENDIX B Rotational Averaging of Cartesian Tensors. REFERENCES. INDEX.

Read more less

Book SynopsisMolecules and Medicine provides, for the first time ever, a completely integrated look at chemistry, biology, drug discovery, and medicine. It delves into the discovery, application, and mode of action of more than one hundred of the most significant molecules in use in modern medicine.Trade Review“Molecules and Medicine is a fascinating introduction to the convergence of chemistry and physiology, and to the emergence of the science of molecular medicine.” (The Nucleus, January 2010) "An interesting and valuable read … .This book is intended for a wide audience and contains much that will engage the specialist and general reader alike." (Chemistry World, July 2008) "...a joy to read...will inspire the field...not only reports on a scientific subject but also creates new dimensions. Bravo to authors Corey, Czako, and Kurti." (Chemical & Engineering News, September 17, 2007)Table of ContentsPart I. Introduction 2 Understanding Structural Diagrams of Organic Molecules 4 Some Common Molecules 23 Proteins and Three-Dimensional Protein Structure 26 Some of the Protein Structures That Appear in This Book 32 Part II. Inflammatory, Cardiovascular and Metabolic Diseases Anti-Inflammatory Agents Acetylsalicylic acid (AspirinTM) 38 Naproxen (AleveTM) 39 How Do Anti-Inflammatory Drugs Work? 40 Other Eicosanoids in Inflammation 41 An Overview of Inflammation 42 Celecoxib (CelebrexTM) 43 Prednisone (DeltasoneTM) 44 Methotrexate (TrexallTM) 46 Allopurinol (ZyloprimTM) 47 Antiasthmatic and Antiallergic Agents Salmeterol (SereventTM) 50 Fluticasone Propionate (FloventTM) 51 Montelukast Sodium (SingulairTM) 52 Tiotropium Bromide (SpirivaTM) 53 Loratadine (ClaritinTM) 54 Type 2 Diabetes An Overview of Metabolic Syndrome 56 Antidiabetic and Cholesterol-Lowering Agents Metformin (GlucophageTM) 60 Glipizide (GlucotrolTM) 61 Pioglitazone (ActosTM) 62 Sitagliptin (JanuviaTM) 63 Atorvastatin (LipitorTM) 64 Ezetimibe (ZetiaTM) 65 Cardiovascular Agents Atenolol (TenorminTM) 68 Enalapril (VasotecTM) 69 Candesartan Cilexetil (AtacandTM) 70 Aliskiren (TekturnaTM) 71 Amlodipine (NorvascTM) 72 Nitroglycerin 73 Clopidogrel Bisulfate (PlavixTM) 74 Digoxin (LanoxinTM) 75 Receptors and Signaling Information Flow into the Cell by Chemical Signaling 78 References for Part II 80 Part III. Reproductive Medicine Oral Contraceptives 90 Testosterone 91 Mifepristone (MifeprexTM) 92 Oxytocin (OxytocinTM) 93 Sildenafil (ViagraTM) 94 Osteoporosis Some Aspects of Osteoporosis 96 Alendronate (FosamaxTM) 97 Calcitriol (RocaltrolTM) 98 Raloxifene (EvistaTM) 99 Teriparatide (ForteoTM) 100 Glaucoma and Antiulcer Agents Latanoprost (XalatanTM) 102 Ranitidine (ZantacTM) 103 Omeprazole (PrilosecTM) 104 References for Part III 105 Part IV. Autoimmune Disease and Organ Transplant A Brief Survey of the Immune System 112 Immunosuppressive Agents Azathioprine (ImuranTM) 122 Mycophenolate Mofetil (CeIlCeptTM) 123 Cyclosporin (NeoralTM) 124 Tacrolimus (PrografTM) 125 FTY720 (Fingolimod) 126 Infectious Diseases Antibiotics Amoxicillin (AmoxilTM) 130 Cefaclor (CeclorTM) 132 Doxycycline (VibramycinTM) 133 Azithromycin (ZithromaxTM) 134 Ciprofloxacin (CiproTM) 135 Trimethoprim (TriprimTM) 136 Amikacin (AmikinTM) 137 Vancomycin (VancocinTM) 138 Linezolid (ZyvoxTM) 139 Isoniazid (LaniazidTM) 140 Ancillary Antibiotics 142 Drug Resistance 143 Antiviral Agents On Viruses and Viral Diseases 146 Acyclovir (ZoviraxTM) 148 Ribavirin (VirazoleTM) 149 Oseltamivir (TamifluTM) 150 Zidovudine (Retrovir, AZTTM) 151 Zalcitabine (HividTM) 152 Nevirapine (ViramuneTM) 153 Efavirenz (SustivaTM) 154 Lopinavir + Ritonavir (KaletraTM) 155 UK427857 (Maraviroc) 156 Antifungal Agents Amphotericin (FungizoneTM) 160 Fluconazole (DiflucanTM) 161 Caspofungin (CancidasTM) 162 Terbinafine (LamisilTM) 163 Antimalarial and Antiparasitic Agents Parasitic Diseases: A Focus on Malaria 166 Chloroquine (ArdenTM) 167 Artemether + Lumefantrine (CoArtemTM) 168 Atovaquone + Proguanil (MalaroneTM) 169 Miltefosine (I mpavidoTM) 170 Nitazoxanide (AliniaTM) 171 Ivermectin (StromectolTM) 172 References for Part IV 173 Part V. Malignant Disease An Overview of Cancer 184 Capecitabine (XelodaTM) 187 Carboplatin (ParaplatinTM) 188 Vinblastine (VelbanTM) 189 Paclitaxel (TaxolTM) 190 Cyclophosphamide (CytoxanTM) 191 Tamoxifen (NolvadexTM) 192 Irinotecan (CamptosarTM) 193 Bleomycin (BlenoxaneTM) 194 Imatinib (GleevecTM) 195 Sunitinib (SutentTM) 196 Bortezomib (VelcadeTM) 197 Ancillary Anticancer Agents 198 References for Part V 200 Part VI. Drugs Acting on the Nervous System Pain and Analgesia Lidocaine (XylocaineTM) 208 Morphine (AvinzaTM) 209 Acetaminophen (Tylenol TM) 210 Fentanyl (DuragesicTM) 211 Sodium Thiopental (Sodium PentothalTM) 212 Gabapentin (NeurontinTM) 213 Diazepam (ValiumTM) 214 Sumatriptan (ImitrexTM) 215 Hypnotics (Insomnia) and Antismoking Zolpidem (AmbienTM) 218 Ramelteon (RozeremTM) 219 Varenicline (ChantixTM) 220 The Brain, Neurotransmission and Molecular Neurotransmitters 221 Neurodegenerative and Psychiatric Diseases Levodopa (LarodopaTM) 224 Donepezil (AriceptTM) 225 Antiepileptic Agents 226 Antianxiety Agents 228 Antidepressants 229 Antipsychotics 232 References for Part VI 233 Glossary 237 Index 249

Read more less

Book SynopsisThis is the first comprehensive systems biology book to focus on its applications in drug discovery and development. It covers all phases of drug discovery and development, discussing their interaction with systems biology. Using real-world examples, the book shows how systems biology can enhance pharmaceutical research.Trade Review“I enjoyed reading this book as it should be essential reading for those involved in drug discovery and development for all others who share an interest in this field.” (International Society for the Study of Xenobiotics, 2012) "In short, this is an indispensable tool for both experienced and early stage investigators and others to understand the current and future impact of systems biology on the drug discovery and development process." (Doody's, 6 January 2012) Table of ContentsPart I: Introduction to Systems Biology Approach. Chapter 1. Introduction to systems biology in drug discovery and development. 1.1 Introduction. Chapter 2. Methods for In Silico Biology: Model Construction and Analysis. 2.1 Introduction. 2.2 Model building. 2.3 Parameter estimation. 2.4. Model analysis. 2.5 Conclusions. Chapter 3. Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways. 3.1 Introduction. 3.2 Statistical modeling. 3.3 Mathematical modeling. 3.4 Feedback and feedforward. 3.5 Conclusions. Chapter 4. Simulation of Population Variability in Pharmacokinetics. 4.1 Introduction. 4.2 PBPK modeling. 4.3 Simulation of pharmacokinetic variability. 4.4 Conclusions and future directions. Part II: Applications to Drug Discovery. Chapter 5. Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery. 5.1 Introduction. 5.2 Typical drug discovery paradigm. 5.3 Integrated drug discovery. 5.4 Drivers of the disease phenotype: clinical endpoints and hypotheses. 5.5 Extracellular disease drivers: mechanistic biotherapeutic models. 5.6 Relevant cell models for clinical endpoints. 5.7 Intracellular disease drivers: signaling pathway quantification. 5.8 Target selection: dynamic pathway modeling. 5.9 Conclusions. Chapter 6. Lead Identification and Optimization. 6.1 Introduction. 6.2 The systems biology toolkit. 6.3 Conclusions. Chapter 7. The role of core biological motifs in dose-response modeling: an example with switch-like circuits. 7.1 Introduction: systems perspective in drug discovery. 7.2 Systems biology and toxicology. 7.3 Mechanistic/computational concepts in a molecular/cellular context. 7.4 Response motifs in cell signaling and their role in dose response. 7.5 Discussion and conclusions. Chapter 8. Mechanism Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development. 8.1 Introduction. 8.2 Challenges in drug discovery and development: the need to bring together PK and PD. 8.3 Methodological aspects and concepts. 8.4 Application during lead optimization. 8.5 Application during clinical candidate selection. 8.6 Entry into human (EIH) preparation and translational PK/PD modeling. 8.7 PK/PD for toxicology study design and evaluation. 8.8 Justification of starting dose, calculation of safety margins, and support of phase I design. 8.9 Phase I and beyond. 8.10 Support of early formulation development. 8.11 Outlook and conclusions. Part III: Applications to Drug Development. Chapter 9. Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases. 9.1 Introduction. 9.2 Modeling angiogenesis. 9.3 Use of rigorous mathematical analysis for gaining insight on drug development. 9.4 Use of angiogenesis models in theranostics. 9.5 Use of angiogenesis models in drug salvage: the virtual patient technology. 9.6 Summary and conclusions. Chapter 10. Systems Modeling Applied to Candidate Biomarker Identification. 10.1 Introduction. 10.2 Biomarker discovery approaches. 10.3 Examples of systems modeling approaches for identification of candidate biomarkers. 10.4 Conclusions. Chapter 11. Simulating Clinical Trials. 11.1 Introduction. 11.2 Types of models used in clinical trial design. 11.3 Sources of prior information for designing clinical trials. 11.4 Aspects of a trial to be designed and optimized. 11.5 Trial simulation. 11.6 Optimizing designs. 11.7 Real world examples. 11.8 Conclusions. Part IV: Synergies with other technologies. Chapter 12. Pathway Analysis in Drug Discovery. 12.1 Introduction: pathway analysis, dynamic modeling, and network analysis. 12.2 Software systems for pathway analysis. 12.3 Pathway analysis in modern drug development pipeline. 12.4 Conclusions. Chapter 13. Functional mapping for predicting drug response and enabling personalized medicine. 13.1 Introduction. 13.2 Functional mapping. 13.3 Predictive modeling. 13.4 Future directions. Chapter 14. Future Outlook of Systems Biology. 14.1 Introduction. 14.2 Systems complexity in biological systems. 14.3 Models for quantitative integration of data. 14.4 Changing requirements for systems approaches during drug discovery and development. 14.5 Better models for better decisions. 14.6 Advancing personalized medicine. 14.7 Improving clinical trials and enabling more complex treatment approaches. 14.8 Collaboration and training for systems biologists. 14.9 Conclusions.

Read more less

Book Synopsis Written by a committee of safety professionals, this book creates a foundation document for the development and application of risk tolerance criteria Helps safety managers evaluate the frequency, severity and consequence of human injury Includes examples of risk tolerance criteria used by NASA, Earthquake Response teams and the International Maritime Organization, amongst others Helps achieve consistency in risk-based decision-making Reduces potential liabilities in the use of quantitative risk tolerance criteria through reference to an industry guidance document Table of ContentsPreface xiii Acknowledgments xv List of Tables xix List of Figures xxi Acronyms and Abbreviations xxv Glossary xxix 1 INTRODUCTION 1 1.1 What is Risk? 1 1.2 Scope of these Guidelines 7 1.3 Objectives of these Guidelines 8 2 FUNDAMENTAL CONCEPTS OF RISK ASSESSMENT AND RISK CRITERIA 11 2.1 A Brief History of Risk Assessment 11 2.2 The Qualitative Approach to Risk Assessment 15 2.3 Technical Aspects of QRA 21 2.4 Quantitative Risk Criteria 31 2.5 The Role of QRA and Risk Criteria 37 2.6 Risk Tolerance as a Function of Societal Values 39 2.7 Definition and Applications of the "As Low as Reasonably Practicable" (ALARP) Principle 44 2.8 Uncertainty and Its Impact on Risk Decision Making 46 3 LEARNING FROM REGULATORY PRECEDENTS 49 3.1 Why Study Risk Criteria? 49 3.2 The Evolution of Risk Criteria in the UK 51 3.3 The Evolution of Risk Criteria in the Netherlands 60 3.4 Comparison of Risk Criteria in the UK and the Netherlands 67 3.5 Learning from and Applying the Precedents 73 4 CONSIDERATIONS IN DEVELOPING RISK CRITERIA 79 4.1 Determine the Need to Establish Risk Criteria 80 4.2 Determine the Risks to be Addressed 82 4.3 Determine/Classify the Population to be Addressed 82 4.4 Determine Which Risk Criteria to Develop 84 4.5 Determine Whether Risk Criteria Will Distinguish Between New and Existing Facilities 85 4.6 Determine Philosophy for Continuing Risk Reduction 87 4.7 Develop Individual Risk Criteria 87 4.8 Develop Societal Risk Criteria 88 4.9 Qualifymalidate the Risk Criteria 88 4.10 Decide on a Philosophy for Apportioning and Scaling the Risk Criteria 91 4.11 Periodically Revalidate the Risk Criteria 98 4.12 Matching the Risk Criteria with the System and with the Risk Estimation Methodology 100 4.13 Risk Criteria in the Multinational Context 102 4.14 Consideration of Short DuratiodHigher Risk Activities 103 5 FUTURE TOPICS 105 5.1 Fostering the Application of Risk-Based Decision Making 105 5.2 Enhancing Risk Assessment Technology 106 Appendix A: Understanding and Using F-N Diagrams 109 Appendix B: Survey of Worldwide Risk Criteria Applications 119 Appendix C: Development of Company Risk Criteria 171 REFERENCES 191 INDEX 207

Read more less

Book SynopsisCatalytic Air Pollution Control: Commercial Technology is the primary source for commercial catalytic air pollution control technology, offering engineers a comprehensive account of all modern catalytic technology.Trade Review"This book will be of benefit to those working in the immediate area of catalytic pollution control, as well as those concerned with broader aspects of environmental chemistry both at the professional and student levels. Librarians are encouraged to ensure this volume is on their shelves." (Platinum Metals Review, March 2010) Table of ContentsPreface. ACKNOWLEDGEMENTS. ACKNOWLEDGEMENTS, FIRST EDITION. ACKNOWLEDGEMENTS, SECOND EDITION. I. FUNDAMENTALS. 1. Catalyst Fundamentals. 1.1 Introduction. 1.2 Catalyzed Verses Non-Catalyzed Reactions. 1.3 Catalytic Components. 1.4 Selectivity. 1.5 Promoters and their Effect on Activity and Selectivity. 1.6 Dispersed Model for Catalytic Component on Carrier: Pt on Al2O3. 1.7 Chemical and Physical Steps in Heterogeneous Catalysis. 1.8 Practical Significance of knowing the Rate-Limiting Step. 2. The Preparation of Catalytic Materials: Carriers, Active Components, and Monolithic Substrates. 2.1 Introduction. 2.2 Carriers. 2.3 Making the Finished Catalyst. 2.4 Nomenclature for Dispersed Catalysts. 2.5 Monolithic Materials as Catalyst Substrates. 2.6 Preparing Monolithic Catalysts. 2.7 Catalytic Monoliths. 2.8 Catalyzed Monoliths Nomenclature. 2.9 Precious Metal Recovery from Monolithic Catalysts. 3. Catalyst Characterization. 3.1 Introduction. 3.2 Physical Properties of Catalysts. 3.3 Chemical and Physical Morphology Structures of Catalytic Materials . 3.4 Techniques for Fundamental Studies. 4. Monolithic Reactors for Environmental Catalysis. 4.1 Introduction. 4.2 Chemical Kinetic Control. 4.3 The Arrhenius Equation and Reaction Parameters. 4.4 Bulk Mass Transfer. 4.5 Reactor Bed Pressure Drop. 4.6 Summary. 5. Catalyst Deactivation. 5.1 Introduction. 5.2 Thermally Induced Deactivation. 5.3 Poisoning. 5.4 Washcoat Loss. 5.5 General Comments on Deactivation Diagnostics in Monolithic Catalysts for Environmental Applications. II. MOBILE SOURCE. 6. Automotive Catalyst. 6.1 Emissions and Regulations. 6.2 The Catalytic Reactions for Pollution Abatement. 6.3 The Physical Structure of the Catalytic Converter. 6.4 First-Generation Converters: Oxidation Catalyst (1976-1979). 6.5 NOx, CO and HC Reduction: The Second Generation: The Three Way Catalyst (1979 - 1986). 6.6 Vehicle Test Procedures (U.S., European and Japanese). 6.7 NOx, CO and HC Reduction: The Third Generation (1986 - 1992). 6.8 Palladium TWC Catalyst: The Fourth Generation (Mid-1990s). 6.9 Low Emission Catalyst Technologies. 6.10 Modern TWC Technologies for the 2000s. 6.11 Towards a Zero-Emission Stoichiometric Spark-Ignit Vehicle. 6.12 Engineered Catalyst Design. 6.13 Lean-Burn Spark-Ignited Gasoline Engines. 7. Automotive Substrates. 7.1 Introduction to Ceramic Substrates. 7.2 Requirements for Substrates. 7.3 Design Sizing of Substrates. 7.4 Physical Properties of Substrates. 7.5 Physical Durability. 7.6 Advances in Substrates. 7.7 Commercial Applications. 7.8 Summary. 8. Diesel Engine Emissions. 8.1 Introduction. 8.2 Worldwide Diesel Emission Standards. 8.3 NOx-Particulate Tradeoff. 8.4 Analytical Procedures for Particulates. 8.5 Particulate Removal. 8.6 NOX Reduction Technologies. 8.7 2007 Commercial System Designs (PM Removal Only). 8.8 2010 Commercial System Approaches under Development (PM and NOx Removal). 8.9 Retrofit and Off-Highway. 8.10 Natural Gas Engines. 9. Diesel Catalyst Supports and Particulate Filters. 9.1 Introduction. 9.2 Health Effects of Diesel Particulate Emissions. 9.3 Diesel Oxidation Catalyst Supports. 9.4 Design/Sizing of Diesel Particulate Filter. 9.5 Regeneration Techniques. 9.6 Physical Properties and Durability. 9.7 Advances in Diesel Filters. 9.8 Applications. 9.9 Summary. 10. Ozone Abatement within Jet Aircraft. 10.1 Introduction. 10.2 Ozone Abatement. 10.3 Deactivation. 10.4 Analysis of In-Flight Samples. 10.5 New Technology. III. STATIONARY SOURCES. 11. Volatile Organic Compounds. 11.1 Introduction. 11.2 Catalytic Incineration. 11.3 Halogenated Hydrocarbons. 11.4 Food Processing. 11.5 Wood Stoves. 11.6 Process Design. 11.7 Deactivation. 11.8 Regeneration of Deactivated Catalysts. 12. Reduction of NOx. 12.1 Introduction. 12.2 Nonselective Catalytic Reduction of NOx. 12.3 Selective Catalytic Reduction of NOx. 12.4 Commercial Experience. 12.5 Nitrous Oxide (N2O). 12.6 Catalytically Supported Thermal Combustion. 13. Carbon Monoxide and Hydrocarbon Abatement from Gas Turbines. 13.1 Introduction. 13.2 Catalyst for CO Abatement. 13.3 Non-Methane Hydrocarbon (NMHC) Removal. 13.4 Oxidation of Reactive Hydrocarbons. 13.5 Oxidation of Unreactive Light Paraffins. 13.6 Catalyst Deactivation. 14. Small Engines. 14.1 Introduction. 14.2 Emissions. 14.3 EPA Regulations. 14.4 Catalyst for Handheld and Nonhandheld Engines. 14.5 Catalyst Durability. IV. NEW AND EMERGING TECHNOLOGIES. 15. Ambient Air Cleanup. 15.1 Introduction. 15.2 Premair® Catalyst Systems. 15.3 Other Approaches. 16. Fuel Cells and Hydrogen Generation. 16.1 Introduction. 16.2 Low-Temperature PEM Fuel Cell Technology. 16.3 The Ideal Hydrogen Economy. 16.4 Conventional Hydrogen Generation. 16.5 Hydrogen Generation from Natural Gas for PEM Fuel Cells. 16.6 Other Fuel Cell Systems. INDEX.

Read more less

Book SynopsisKinase Inhibitor Drugs covers a wide and comprehensive range of topics about kinase-targeted inhibitors in cancer therapy, one of the hottest drug targets in modern drug discovery.Trade Review"In conclusion, I strongly recommend this book to anyone who is interested and new to the field of kinase inhibitors. Indeed, I believe this book should not merely sit on the shelves of kinase experts, but should be used frequently for reference." (ChemMedChem, 2010) "Delivers what the title promises: a comprehensive treatment of drugs that inhibit kinases. ... Will be interesting to any chemist or biologist desiring a behind-the-scenes look at modern strategies of drug discovery and their practical applications to some challenging targets." (Journal of Medicinal Chemistry, April 2010)Table of ContentsPREFACE. CONTRIBUTORS. PART I GROWTH FACTOR INHIBITORS: VEGFR2, ERBB2, AND OTHER KINASE. 1 Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis (Connie L. Sun, James G. Christensen, and Gerald McMahon). 2 Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor (Karen Lackey and G. Stuart Cockerill). 3 Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor (Philip A. Harris and Jeffrey A. Stafford). 4 Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor (Michael Michaelides and Daniel H. Albert). 5 Discovery of Motesanib (Andrew S. Tasker and Vinod F. Patel). 6 Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor (Rajeev S. Bhide and Joseph Fargnoli). 7 S tructure-Based Design and Characterization of Axitinib (Robert S. Kania). PART II GROWTH FACTOR INHIBITORS: MEK INHIBITORS. 8 Road to PD0325901 and Beyond: The MEK Inhibitor Quest (Judith S. Sebolt-Leopold and Alexander J. Bridges). 9 Discovery of Allosteric MEK Inhibitors (Eli Wallace and James F. Blake). PART III CELL CYCLE KINASE INHIBITORS: AURORA KINASE AND PLK INHIBITORS. 10 Discovery of MK-0457 (VX-680) (Julian M. C. Golec). 11 Discovery of PHA-739358 (Daniele Fancelli and Jürgen Moll). 12 Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity (Kevin M. Foote and Andrew A. Mortlock). 13 Case Study of Aurora-A Inhibitor MLN8054 (Christopher F. Claiborne and Mark G. Manfredi). 14 Discovery of GSK461364: A Polo-like Kinase 1 Inhibitor for the Treatment of Cancer (Kevin W. Kuntz and Kyle A. Emmitte). PART IV RELATED SPECIAL TOPICS. 15 Pharmacogenomics of Dasatinib (Sprycel) (Fei Huang and Edwin A. Clark). 16 Practical Use of Computational Chemistry in Kinase Drug Discovery (James M. Veal). 17 Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome (Victoria A. Feher and J. David Lawson). 18 Fragment-Based Drug Discovery of Kinase Inhibitors (Daniel A. Erlanson). 19 Protein Kinase Structural Biology: Methods and Strategies for Targeted Drug Discovery (Clifford D. Mol, Kengo Okada, and David J. Hosfield). INDEX.

Read more less

Book SynopsisThe science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development. With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the good inhibitionsdesirable pharmacological effectsand bad inhibitionsdrugdrug interactions and toxicity. The book discusses: The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment The maTrade Review"The description of each topic is clear, well organized and informative, making the book a useful or even essential high-level handbook." (ChemMedChem, November 2010) Table of ContentsPREFACE. CONTRIBUTORS. PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES. 1. The Drug Discovery Process (Gerald T. Miwa). 2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors (Geraldine Harriman, Amy Elder, and Indranath Ghosh). 3. Bioanalytical Technologies in Drug Discovery (Jing-Tao Wu). 4. Safety Biomarkers in Drug Development: Emerging Trends and Implications (Eric R. Fedyk). 5. The Role of Drug Metabolism in Drug Discovery (Tonika Bohnert and Liang-Shang Gan). 6. Applied Pharmacokinetics in Drug Discovery and Development (Hua Yang, Xingrong Liu, Anjaneya Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu). PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES—THE UNDESIRABLE INHIBITION. 7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes (R. Scott Obach). 8. Cytochrome P450 Induction (Edward L. LeCluyse, Michael W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi). 9. Inhibition of Drug-Metabolizing Enzymes in Gastrointestinal Tract and Its Influence on the Drug–Drug Interaction Prediction (Aleksandra Galetin and J. Brian Houston). 10. Enzyme Inhibition in Various In Vitro Systems (Ping Zhou). 11. Cytochrome P450 Degradation and Its Clinical Relevance (Mingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia). 12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition (Michael B. Fisher). 13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes (Albert P. Li and Chuang Lu). 14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors (Suresh K. Balani). 15. Transporter–Xenobiotic Interactions: An Important Aspect of Drug Development Studies (Gang Luo, Richard Ridgewell, and Thomas Guenthner). 16. Polymorphisms of Drug Transporters and Their Clinical Implications (Cindy Q. Xia and Johnny J. Yang). 17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation (Lisa L. von Moltke and David J. Greenblatt). 18. Predicting Interindividual Variability of Metabolic Drug–Drug Interactions: Identifying the Causes and Accounting for Them Using Systems Approach (Amin Rostami-Hodjegan). PART III. INHIBITION OF THE DRUG TARGET ENZYMES—THE DESIRABLE INHIBITION. 19. NF-κB: Mechanism, Tumor Biology, and Inhibitors (Lenny Dang). 20. G-Protein-Coupled Receptors as Drug Targets (Wenyan Miao and Lijun Wu). 21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain (Yi Liu and Ning Qin). 22. Targeting the mTOR Pathway for Tumor Therapeutics (Wei Chen). 23. HIV-1 Protease Inhibitors as Antiretroviral Agents (Sergei V. Gulnik, Elena Afonina, and Michael Eissenstat). INDEX.

Read more less

Book SynopsisThis book will describe fundamentals and recent developments in the area of Self-Assembled Supramolecular Architecture and their relevance to the understanding of the functionality of membranes as delivery systems for active ingredients.Table of ContentsPreface vii Contributors xi 1. Physics of Self-Assembly of Lyotropic Liquid Crystals 1 Raffaele Mezzenga 2. Rheological Theory and Simulation of Surfactant Nematic Liquid Crystals 21 Alejandro D. Rey and E. E. Herrera-Valencia 3. Dividing Planes of Hexagonal HII Mesophase 79 Vesselin Kolev, Abraham Aserin, and Nissim Garti 4. Nanocharacterization of Lyotropic Liquid Crystalline Systems 97 Patrick G. Hartley and Hsin-Hui Shen 5. Self-Assembly in Lipidic Particles 129 Anan Yaghmur and Otto Glatter 6. Hierarchically Organized Systems Based on Liquid Crystalline Phases 157 Chandrashekhar V. Kulkarni and Otto Glatter 7. Synthesis and Alignment of Nanostructured Materials Using Liquid Crystals 193 Idit Amar-Yuli, Abraham Aserin, and Nissim Garti 8. Recent Developments in Lyotropic Liquid Crystals as Drug Delivery Vehicles 219 Dima Libster, Abraham Aserin, and Nissim Garti 9. Stimuli-Responsive Lipid-Based Self-Assembled Systems 257 Ben J. Boyd and Wye-Khay Fong 10. Nonlamellar Lipid Liquid Crystalline Structures at Interfaces 289 Debby P. Chang and Tommy Nylander 11. Multicompartment Lipid Nanocarriers for Targeting of Cells Expressing Brain Receptors 319 Claire Géral, Angelina Angelova, Borislav Angelov, Valérie Nicolas, and Sylviane Lesieur Index 357

Read more less

Book SynopsisThis book specifically addresses the safety aspects of compatibility for drugs and their delivery devices and containers. The author deals with issues such as how the leachables impact safety of a therapeutic product and, more importantly, how one ascertains the magnitude of the impact.Trade Review"The book provides a very detailed review of approaches for generating and further investigating extractables and leachables results, with advice on the levels of investigation appropriate to each stage of product development." (BTS Newsletter, Summer 2010) Table of ContentsPreface and Acknowledgments xv Part A General Concepts 1 1. Introduction 3 General Discussion 3 Key Definitions 6 The Interacting Parties 6 Extractables versus Leachables 7 Regulatory Perspectives for Performing Compatibility and/or Safety Assessments 13 The U.S. Food and Drug Administration Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics 14 European Medicines Agency (EMEA) Guideline on Plastic Immediate Packaging Materials 15 FDA Guidance for Industry Inhalation Products 18 Medical Devices 20 An Overview of Strategies for Performing Safety Assessments 21 The Generalized Strategy for Safety Assessments 22 Moving Forward 24 References 25 2. Nomenclature and General Concepts 27 General 27 Nomenclature 27 Primary Definitions 28 Constituents of a Material or Construct 29 Classification of Extracting Media 31 Classification of Extraction Strategies 32 Example Extraction Conditions Applied to a Model System 39 Correlation 43 Factors That Influence the Linking of Extractables and Leachables 44 A Hierarchy for Linkages between Extractables and Leachables 44 Decisions Concerning the Required Rigor for Linkages 47 Circumstances Requiring the Linking of Extractables and Leachables 48 Identification and Quantitation 50 Risks and Risk Management 55 Risk Categories Related to Biological Assessment of Medical Devices 58 Risk Categories Related to Assessment of Primary Packaging and/or Container–Closure Systems 58 The General Dimensions of Risk 64 Utilization of Risk Classification Profiles 68 Risk Classification in Indirect Contact Situations 71 The Construct Itself as a Contributor to Risk 73 References 74 3. Extractables, Leachables, and the Product Life Cycle 77 General 77 Discussion of the Components of the Master Flow Diagram 78 Observations 83 Application of the Process Map 87 Part B Material Characterization 89 4. Material Screening and Characterization 91 Overview 91 General Principles 94 Compendial Compliance 97 United States Pharmacopeia 98 Japanese Pharmaceopeia 101 European Pharmacopeia 102 Compositional Characterization, General Concepts 103 Compositional Characterization by Collecting Available Material Information 104 General 104 Collecting Extractables Information from the Material Supplier 106 Compositional Characterization by Material Testing, Extractables Survey 112 Extractables Survey: Extraction 112 Case Studies: The Influence of Extraction Medium on the Extractables Survey 121 Extractables Survey: Extract Analysis 124 Case Study: Extractables Survey for Plastic Tubing Materials 131 Case Study: Extractables Survey for an Elastomer Used in OINDP 136 Case Study: Extractables Survey for a Rubber Closure Used with Semisolid Drug Products 137 Case Study: Extractables Survey for Filter Cartridges Used in Downstream Processing of Pharmaceuticals 138 Bibliography of Analytical Methods 139 Reconciliation as a Survey Tool 140 Case Study: TOC Reconciliation; Characterization of a Polyolefin Material 141 Use of Extractables Information in Safety Assessment: Extractables Profile, Total Pool, and Total Available Pool 142 Extractions to Establish the Total Pool and Total Available Pool 143 Case Study: Total Pool Determination by Successive Extraction 145 Recap: Components of a Complete Extractables Assessment 146 Caveats in Using Extractables Information for Safety Assessment 149 Chemical Characterization: Device Perspective per ISO 10993-18 152 References 154 Part C Construct Qualification 157 5. The Prototype Stage 159 General Comments 159 The Simulation Study 161 Generating the Simulating Extract 162 Simulating the Contact Parameters 164 Simulating the Therapeutic Product 166 Simulating the Exposure Parameters 169 Analyzing the Simulating Extract 171 Case Study: Modeling of the Impact of Solubilizing Agents on Leachables Accumulation 172 Case Study: Accumulation of Organic Leachables from Plastic Biopharmaceutical Process Containers 174 Case Study: Accumulation of Label-Related Leachables in a Solid Dosage Form 179 Case Study: Accumulation of Caprolactam Oligomers Leached from Nylon-6 Material 180 Application of the Analytical Threshold 181 The Preliminary Toxicological Assessment 184 Case Study: Assessment of Cyclohexanone Limits for Containers 188 Exiting the Prototype Stage 188 References 189 6. The Early Development Stage 191 General Comments 191 Target Leachables 192 Method Development, Evaluation, and Validation 194 Method Development (Optimization) 195 Prerequisites to Method Optimization 195 Overview of the Method Optimization Process 197 Conduct of a Method Optimization Study 200 Primary Performance Assessment 201 Troubleshooting Guide 202 Secondary Performance Assessment 204 System Suitability 205 Robustness 205 Exiting Method Development–Optimization 206 The Method Evaluation Process 206 General 206 Aspects of the Evaluation and Validation Processes 207 Overview of the Method Evaluation Process 207 Template for the Conduct of a Method Evaluation Study 209 Validation 214 Case Study: Validation of an LC/MS Method for the Quantitation of Leachables from a Packaging System 215 General 215 Experimental 216 Validation Study 218 Case Study: Validation of an HPLC Method for Quantitating Stopper Leachables in a Complex Surfactant Vehicle 225 General 225 Validation 225 Exiting the Early Development Stage 228 References 228 Part D Construct Validation 229 7. Late Stage Product Development 231 General: The Migration Study 231 Design of the Migration Study 233 EMEA Guideline on Plastic Immediate Packaging Materials 233 FDA Guidance 233 Optimal Design of a Migration Study 234 Interpretation of the Migration Study: Toxicological Assessment 238 Disaster Management 238 Class A Disaster: Unusual or Unexpected Change in the Concentration of a Target Leachable 239 Class B Disaster: A Previously Unobserved Response is Obtained During Testing 241 Documenting a Disaster Investigation 242 Specificity Check in Drug Product Analysis Methods 242 Product Stability Issues Associated with Leachables 244 References 245 8. Submission 249 General Discussion 249 Dossier Format: The Common Technical Document 250 Contents of the CTD Sections Relevant to Container Closure Systems and Their Safety Assessment 252 Section 3.2.P.7, Description 252 Section 3.2.P.2.4, Suitability 254 Closing Observations 262 References 263 9. Launch 265 Part E Product Maintenance 271 10. Product Maintenance 273 General Discussion 273 Ongoing Quality Control 275 General 275 Incoming Raw Materials 275 Manufactured In-Process Goods 278 Finished Goods (Final Product) 279 Process of Developing–Implementing QC Extractables Specifications 281 Change Control 282 General 282 Change Control Impact Assessment 285 Evaluation Recommendation 295 Factors to Consider When Contemplating Changes to Registered Products 296 Case Study: Differential Approach 297 Overview 297 General Test Strategy 297 Experimental 298 Results and Discussion 299 Principles for Judging Toxicological Equivalency 304 Disaster Management During Product Maintenance 305 Atypical Manufacturing During Product Maintenance 305 Product Use Field Issues Encountered During Product Maintenance 309 Changes in Product Registration Requirements During Product Maintenance 312 Exiting the Product Maintenance Stage 313 References 313 11. Retirement 315 12. Focus on Emerging Concepts 319 Overview 319 Plastic Materials used in Manufacturing Applications 320 General 320 Regulatory Requirements 321 Industry Recommendations 322 Case Study: Leachables Evaluation for Bulk Drug Substance 326 Process for Performing Extractables and Leachables Assessments for Disposable Materials Used in Bioprocessing 327 A Matter of Semantics 328 Best Demonstrated Practices in Extractables Assessments 331 The Broader Context of Suitability for Use 337 An Important Practical Consideration 340 Future Considerations 342 References 344 Appendix: Materials Used in Pharmaceutical Constructs and Their Associated Extractables 347 References 370 Index 371

Read more less

Book SynopsisThe concepts, applications, and practical issues of Quality by Design Quality by Design (QbD) is a new framework currently being implemented by the FDA, as well as EU and Japanese regulatory agencies, to ensure better understanding of the process so as to yield a consistent and high-quality pharmaceutical product. QbD breaks from past approaches in assuming that drug quality cannot be tested into products; rather, it must be built into every step of the product creation process. Quality by Design: Perspectives and Case Studies presents the first systematic approach to QbD in the biotech industry. A comprehensive resource, it combines an in-depth explanation of basic concepts with real-life case studies that illustrate the practical aspects of QbD implementation. In this single source, leading authorities from the biotechnology industry and the FDA discuss such topics as: The understanding and development of the product''s critical quality atTable of ContentsForeword xiii Preface xv Preface to the Wiley Series on Biotechnology and Related Topics xvii Contributors xix 1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1 Rohin Mhatre and Anurag S. Rathore 1.1 Introduction 1 1.2 Critical Quality Attributes 2 1.3 An Overview of Design Space 3 1.4 Raw Materials and their Impact on QbD 4 1.5 Process Analytical Technology 4 1.6 The Utility of Design Space and QbD 5 1.7 Conclusions 7 2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9 Steven Kozlowski and Patrick Swann 2.1 Introduction 9 2.2 Quality by Design 10 2.3 Relevant Product Attributes 11 2.4 Manufacturing Process 14 2.5 Developing a Design Space 18 2.6 Uncertainty and Complexity 22 2.7 Future Horizons 23 2.8 QbD Submission Thoughts 25 2.9 Implementation Plans 26 2.10 Summary 27 3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31 David L. Narum 3.1 Introduction 31 3.2 The Malaria Genome and Proteome 34 3.3 Expression of Two Malaria Antigens in P. pastoris 34 3.4 Summary 46 4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53 Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman 4.1 Introduction 53 4.2 Examples of Criticality Determination 60 4.3 Conclusion 81 5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85 Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore 5.1 Introduction 85 5.2 Approach Toward Process Characterization 87 5.3 Risk Analysis 88 5.4 Small-Scale Model Development and Qualification 89 5.5 Design of Experiment Studies 94 5.6 Worst Case Studies 96 5.7 Definition of Design Space 99 5.8 Definition of Validation Acceptance Limits 103 5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106 6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111 Peter K. Watler and John Rozembersky 6.1 Introduction 111 6.2 Applications of TFF in Biotechnology 113 6.3 Tangential Flow Filtration Operating Principles 113 6.4 TFF Design Objectives 115 6.5 Membrane Selection 115 6.6 TFF Operating Parameter Design 118 6.7 TFF Diafiltration Operating Mode Design 122 6.8 Summary 125 7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127 Douglas J. Cecchini 7.1 Introduction 127 7.2 Establishing Design Space for Purification Processes during Process Development 128 7.3 Applications of Design Space 131 7.4 Cell Harvest and Product Capture Steps 131 7.5 Protein A Capture Column 136 7.6 Hydrophobic Interaction Chromatography 137 7.7 Anion Exchange Chromatography 138 7.8 Summary 141 8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143 Gail Sofer and Jeffrey Carter 8.1 Introduction 143 8.2 Current and Future Approaches to Virus Clearance Characterization 143 8.3 Benefits of Applying Design Space Principles to Virus Clearance 144 8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145 8.5 Developing a Virus Clearance Design Space 148 8.6 Staying in the Design Space 156 8.7 Conclusion 157 9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161 Kingman Ng and Natarajan Rajagopalan 9.1 Introduction 161 9.2 Quality by Design (QbD) Approach 162 9.3 Target Product Profile (TPP) 163 9.4 Molecular Degradation Characterization 164 9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166 9.6 Preformulation Characterization 167 9.7 Initial Formulation Risk Assessments 168 9.8 Formulation Optimization and Design Space 169 9.9 Selection of Solution Formulation Composition 171 9.10 Summary 173 10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175 Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee 10.1 Introduction: QbD in Biologics Product Development 175 10.2 Risk Assessment Process 177 10.3 Examples 178 10.4 Conclusions 191 11 QbD FOR RAW MATERIALS 193 Maureen Lanan 11.1 Introduction 193 11.2 Background 194 11.3 Current Practice for Raw Materials 195 11.4 QbD in Development 195 11.5 QbD in manufacturing 196 11.6 QbD for organizations 197 11.7 Tests Available 197 11.8 Conclusions and Future Prospects 207 12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211 Michael Molony and Cenk Undey 12.1 Introduction 211 12.2 Cell Culture and Fermentation PAT Tools 214 12.3 Purification PAT Tools 223 12.4 Formulation PAT Tools 228 12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230 12.6 Chemometrics and Advanced Process Control Tools 232 12.7 The power of PLS and PCA 233 12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240 12.9 Challenges for Implementation of PAT Tools 244 12.10 Future PAT Tools 247 13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255 Duncan Low and Joseph Phillips 13.1 Introduction 255 13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256 13.3 Process Analytical Technology (PAT) 261 13.4 Quality by Design 263 13.5 Implementing QbD and PAT 266 13.6 Conclusions 282 Acknowledgments 283 References 283 Index 287

Read more less

Book SynopsisThis dictionary provides a tool for translating research results, promotes the exchange of information, and enhances scientists' understanding of the wealth of data published in different languages. It includes 7,000 terms translated into nine languages: English, Chinese, French, Italian, Japanese, Portuguese, Russian, Spanish, and Ukrainian.Table of ContentsList of Contributors. Preface. Prefaces to National Language Versions. Scientific and Lexicographic References. Structure of the Dictionary. Nine Language Dictionary. National Language Keys. Annex 1 English and National abbreviations. Annex 2 Standard testing techniques.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisSyndiotactic Polystyrene (SPS), synthesized in a laboratory for the first time in 1985, has become commercialized in a very short time, with wide acceptance on the global plastics market. Written by leading experts from academia and industry from all over the world, Syndiotactic Polystyrene offers a comprehensive review of all aspects of SPS of interest to both science and industry, from preparation and properties to applications. This essential reference to SPS covers: The preparation of syndiotactic polystyrene by half-metallocenes and other transition metal catalysts The structure and fundamental properties, especially morphology and crystallization and solution behavior The commercial process for SPS manufacturing Properties, processing, and applications of syndiotactic polystyrenes Polymers based on syndiotactic polystyrenes, for example, by functionalization and modification, and nTable of ContentsPREFACE. CONTRIBUTORS. ABOUT THE EDITOR. PART I INTRODUCTION. 1. Historical Overview and Commercialization of Syndiotactic Polystyrene (Michael Malanga, Osamu Isogai, Takeshi Yamada, Shigeo Iwasaki, and Masahiko Kuramoto). 1.1 Discovery of Syndiotactic Polystyrene (SPS). 1.2 Early Years of Development (1985–1989). 1.3 Intense Development Years (1989–1996). 1.4 Initial Commercial Launch Stage (1996–2001). 1.5 Years 2001–2007. PART II PREPARATION OF SYNDIOTACTIC POLYSTYRENE. 2. Transition Metal Catalysts for Syndiotactic Polystyrene (Norio Tomotsu, Thomas H. Newman, Mizutomo Takeuchi, Richard Campbell Jr., and Jürgen Schellenberg). 2.1 Introduction. 2.2 Transition Metal Compounds. 2.3 Summary. References. 3. Cocatalysts for the Syndiospecific Styrene Polymerization (Norio Tomotsu, Hiroshi Maezawa, and Thomas H. Newman). 3.1 Introduction. 3.2 MAO. 3.3 Boron Compounds. 3.4 Other Chemicals. 3.5 Summary. References. 4. Mechanisms for Stereochemical Control in the Syndiotactic Polymerization of Styrene (Norio Tomotsu, Thomas H. Newman, and Richard Campbell Jr.). 4.1 Introduction. 4.2 Insertion of the Growing Polymer Chain into the Double Bond of Styrene. 4.3 Stereochemistry of the Styrene Insertion. 4.4 Effects of Hydrogenation of the Catalyst. 4.5 Active Site Species. 4.6 Theoretical Analysis of the Catalyst. 4.7 Kinetic Analysis of Styrene Polymerization. 4.8 Conclusions. References. 5. Copolymerization of Ethylene with Styrene: Design of Efficient Transition Metal Complex Catalysts (Kotohiro Nomura). 5.1 Introduction. 5.2 Ethylene/Styrene Copolymers: Microstructures, Thermal Properties, and Composition Analyses. 5.3 Ethylene/Styrene Copolymerization Using Transition Metal Complex–Cocatalyst Systems. 5.4 Summary and Outlook. References. 6. Structure and Properties of Tetrabenzo[a,c,g,i]fl uorenyl-Based Titanium Catalysts (Rüdiger Beckhaus, Kai Schröder, and Jürgen Schellenberg). 6.1 Introduction. 6.2 The Tbf Ligand. 6.3 Tbf Lithium. 6.4 Tbf Titanium(III) Derivatives. 6.5 Tbf Titanium(IV) Derivatives. 6.6 Dynamic and Polymerization Behavior of Tetrabenzofluorenyl Titanium Complexes. 6.7 Conclusions. References. 7. Rare-Earth Metal Complexes as Catalysts for Syndiospecific Styrene Polymerization (Klaus Beckerle and Jun Okuda). 7.1 Introduction. 7.2 Metallocene Catalysts. 7.3 Constrained Geometry Catalysts. 7.4 Half-Sandwich Catalysts. 7.5 Nonmetallocene Catalysts. 7.6 Conclusion. References. 8. Syndiospecific Styrene Polymerization with Heterogenized Transition Metal Catalysts (Kyu Yong Choi). 8.1 Introduction. 8.2 Kinetics of Syndiospecific Polymerization with Heterogeneous Metallocene Catalysts. 8.3 Nascent Morphology of Syndiotactic Polystyrene. 8.4 Concluding Remarks. References. PART III STRUCTURE AND FUNDAMENTAL PROPERTIES OF SYNDIOTACTIC POLYSTYRENE. 9. Structure, Morphology, and Crystallization Behavior of Syndiotactic Polystyrene (Andrea Sorrentino and Vittoria Vittoria). 9.1 Introduction. 9.2 Polymorphic Behavior of SPS. 9.3 Morphology of the Zigzag Forms. 9.4 Morphology of the Mesomorphic Phases. 9.5 Thermodynamic and Kinetics of Crystallization. 9.6 Melting Behavior. 9.7 Structure and Properties of the Crystallized Samples. References. 10. Preparation, Structure, Properties, and Applications of Co-Crystals and Nanoporous Crystalline Phases of Syndiotactic Polystyrene (Gaetano Guerra, Alexandra Romina Albunia, and Concetta D’Aniello). 10.1 Introduction. 10.2 Co-Crystals. 10.3 Nanoporous Crystalline Phases. 10.4 Conclusions and Perspectives. 10.5 Acknowledgments. References. 11. Crystallization Thermodynamics and Kinetics of Syndiotactic Polystyrene (Tomoaki Takebe and Komei Yamasaki). 11.1 Introduction. 11.2 Theoretical Background. 11.3 Equilibrium Melting Point of SPS. 11.4 Analyses of Spherulitic Growth Rate G . 11.5 Comparison Between SPS and IPS. References. PART IV COMMERCIAL PROCESSES FOR MANUFACTURING OF SYNDIOTACTIC POLYSTYRENE. 12. Processes for the Production of Syndiotactic Polystyrene (Masao Aida, David Habermann, Hans-Joachim Leder, and Jürgen Schellenberg). 12.1 Introduction. 12.2 Monomer Purification Section. 12.3 Catalyst Section. 12.4 Polymerization Section. 12.5 Styrene Stripping Section. 12.6 Deactivating Section. 12.7 Pelletizing Section. 12.8 Blending Section. 12.9 Shipping Section. References. PART V PROPERTIES, PROCESSING, AND APPLICATIONS OF SYNDIOTACTIC POLYSTYRENE. 13. Properties of Syndiotactic Polystyrene (Tomoaki Takebe, Komei Yamasaki, Keisuke Funaki, and Michael Malanga). 13.1 Introduction. 13.2 Rheological Properties of SPS. 13.3 Basic Physical Mechanical Properties of SPS. 13.4 Orientation of SPS and Properties of Oriented SPS. 13.5 Other Important Properties of SPS. References. 14. Melt Processing of Syndiotactic Polystyrene (David Bank, Kevin Nichols, Harold Fowler, Jason Reese, and Gerry Billovits). 14.1 Introduction. 14.2 Compounding. 14.3 Injection Molding. 14.4 Sheet and Film Extrusion. 14.5 Film Processing and Fabrication. 14.6 Fiber Spinning. References. 15. Applications of Syndiotactic Polystyrene (Tom Fiola, Akihiko Okada, Masami Mihara, and Kevin Nichols). 15.1 Introduction. 15.2 The Performance Capabilities of SPS. 15.3 Connectors for Automotive and Electronic Applications. 15.4 Electronic Components: Plated and Non-Plated. 15.5 Industrial and Appliance Components. References. 16. Blends of Syndiotactic Polystyrene with Polyamide (Kevin Nichols, Akihiko Okada, and Hiroki Fukui). 16.1 Introduction. 16.2 Composition of SPS/Nylon Blends. 16.3 Properties of SPS/Nylon Blends. 16.4 Applications of SPS/Nylon Blends. References. 17. Blends of Syndiotactic Polystyrene with Polystyrenes (Tomoaki Takebe, Komei Yamasaki, Akihiko Okada, and Takuma Aoyama). 17.1 Introduction. 17.2 SANS Measurements. 17.3 Theoretical Background. 17.4 Tacticity Effect on Miscibility. 17.5 Properties of Blends of SPS and APS. References. 18. Compatibilizers for Impact-Modifi ed Syndiotactic Polystyrene (Tomoaki Takebe, Akihiko Okada, and Nobuyuki Sato). 18.1 Introduction. 18.2 Morphological Analyses of HISPS. 18.3 Morphology of SPS/PPO Binary Blends. 18.4 Compatibilizer Effects. References. PART VI POLYMERS BASED ON SYNDIOTACTIC POLYSTYRENES. 19. Functionalization and Block/Graft Reactions of Syndiotactic Polystyrene Using Borane Comonomers and Chain Transfer Agents (T. C. Mike Chung). 19.1 Introduction. 19.2 Functionalization of SPS via Borane Comonomers. 19.3 Functionalization of SPS via Borane Chain Transfer Agents. 19.4 Summary. 19.5 Acknowledgment. References. 20. Nanocomposites Based on Syndiotactic Polystyrene (O Ok Park and Mun Ho Kim). 20.1 Introduction. 20.2 Polymer Nanocomposites and Microstructure. 20.3 Fabrication of Polymer Nanocomposites. 20.4 Characterization of Polymer Nanocomposites. 20.5 Preparation of SPS Nanocomposites. 20.6 Properties of SPS Nanocomposites. 20.7 Final Remarks. References. INDEX.

Read more less

Book SynopsisA collection of current knowledge of phytochemicals and health Interest in phenolic phytochemicals has increased as scientific studies indicate these compounds exhibit potential health benefits. With contributions from world leaders in this research area, Plant Phenolics and Human Health: Biochemistry, Nutrition, and Pharmacology offers an essential survey of the current knowledge on the capacity of specific micronutrients present in ordinary diets to fight disease. The coverage in this resource: Explains the presence and biochemical properties of phenolics present in fruits and vegetables, as well as in foods derived from their plant sources Provides biochemical explanations on how certain plant phenolics fight cardiovascular and neurodegenerative diseases, cancer, and other widespread pathologies Focuses on certain phenolics, e.g., flavonoids, stilbenes, and curcuminoids, and provides insights on the biocheTrade Review"Some 62 eminent researchers from 14 countries have contributed to the book's 21 chapters, each offering a comprehensive account of what is currently happening at the cutting edge of such intersecting disciplines as food science, nutrition, medicine, and pharmaceutical research. Learned updates to this topic of plant phenolics will probably be forthcoming every five to ten years." (CHOICE, 2010) Table of ContentsPREFACE. CONTRIBUTORS. 1 Dietary Flavonoids and Phenolic Compounds (Indu B. Jaganath and Alan Crozier). 2 Bioavailability of Flavanols and Phenolic Acids (Laure Poquet, Michael N Clifford, and Gary Williamson). 3 Biochemical Actions of Plant Phenolics Compounds: Thermodynamic and Kinetic Aspects (Cesar G. Fraga, Gulcin Sagdicoglu Celep, and Monica Galleano). 4 Flavonoids–Membrane Interactions: Consequences for Biological Actions (Sandra V. Verstraeten, Cesar G. Fraga, and Patricia I. Oteiza). 5 The Biochemistry Behind the Potential Cardiovascular Protection by Dietary Flavonoids (Wai Mun Loke, Jonathan M. Hodgson, and Kevin D. Croft). 6 Dietary Flavanols: Biochemical Basis of Short-Term and Longer-Term Vascular Responses (Tankred Schewe, Yvonne Steffen, Elisabeth Kravets and Helmut Sies). 7 Green Tea Catechins: Anticancer Effects and Molecular Targets (Naghma Khan and Hasan Mukhtar). 8 Flavonols: Metabolism, Bioavailability, and Health Impacts (Junji Terao). 9 Flavonols: Biochemistry Behind Cardiovascular Effects (Francisco Pérez-Vizcaı´no and Juan Duarte). 10 Metabolism, Bioavailability, and Analysis of Dietary Isoflavones (Adrian A. Franke, Brunhild M. Halm, Kerry Kakazu and Xingnan Li). 11 Phytoestrogens Up-regulate Antioxidant Genes (Consuelo Borrás and Jose Viña). 12 Dietary Isoflavones: Cardiovascular Actions and Activation of Cellular Signalling Pathways (Richard C. M. Siow and Giovanni E. Mann). 13 Bioavailability and Metabolism of Resveratrol (Cristina Andres-Lacueva, Mireia Urpi-Sarda, Raul Zamora-Ros, and Rosa M. Lamuela-Raventos). 14 Resveratrol: Biochemistry and Functions (Samarjit Das, Hannah R. Vasanthi, and Dipak K. Das). 15 Resveratrol: The Biochemistry Behind its Anticancer Effects (Joydeb K. Kundu and Young-Joon Surh). 16 Curcumin: The Biochemistry Behind Its Anticancer Effects (Preetha Anand, Ajaikumar B. Kunnumakkara, and Bharat B. Aggarwal). 17 Plant Phenolic Compounds: Modulation of Cytoprotective Enzymes and Nrf2/ARE Signaling (Siwang Yu, Ka Lung Cheung, Wenge Li and Ah-Ng Kong). 18 Phenolics in Aging and Neurodegenerative Disorders (Vittorio Calabrese, Marzia Perluigi, Carolin Cornelius, Raffaella Coccia, Fabio Di Domenico, Giovanni Pennisi, Chiara Cini and Albena T. Dinkova-Kostova). 19 Natural Phenolics and Metal Metabolism in Neurodegenerative Diseases (Baolu Zhao). 20 Epidemiology behind Fruit and Vegetable Consumption and Cancer Risk with Focus on Flavonoids (Marta Rossi, Eva Negri, Cristina Bosetti, Claudio Pelucchi, and Carlo La Vecchia). 21 Phenylpropanoid Metabolism in Plants: Biochemistry, Functional Biology, and Metabolic Engineering (Alberto B. Landolino and Douglas R. Cook). INDEX.

Read more less

Book SynopsisThe second volume in a series, Organic Synthesis: State of the Art 2005-2007 will provide you with a convenient, compact summary of the state of the art of organic synthesis. This reference guide will quickly lead you to the most important recent developments like how scientists can now prepare ketones by directly combining aldehydes with terminal alkenes. Inside, you will find detailed analysis of more than twenty total syntheses, including the Davies Synthesis of (-)-Colombiasin A and (-)-Elisapterosin B, the Overman Synthesis of (-)-Sarain A, and the Sorensen Synthesis of (-)-Guanacastepene E.Trade Review"Provides a rich source of information for the practicing chemist and highlights the diversity of reactions and methods in use." (Journal of Medicinal Chemistry)Table of ContentsPreface. 1. Synthesis of (-)- Littoralisone. 2. Enantiocontrolled Construction of Oxygenated and Animated Stereogenic Centers. 3. Catalytic Enantioselective Construction of Alkylated Stereogenic Centers. 4. Catalytic Enantioselective Aldol/Mannich Reactions Leading to Extended Arrays of Stereogenic Centers. 5. Alternative Strategies for the Construction of Extended Arrays of Stereogenic Centers. 6. Synthesis of(-)- Avrainvillamide and (+)- Stephacidin B. 7. Best Synthetic Methods: Oxidation. 8. Best Synthetic Methods: Reduction. 9. Selective Reactions of Alkenes. 10. Synthesis of the Potent FBBP12 Ligand Antascomicin B. 11. Best Synthetic Methods: Carbon-Carbon Bond Formation. 12. Enantioselective Construction of Quaternary Centers. 13. Pd-Mediated Arylation of Aromatic and Hetero Aromatic Rings. 14. The Overman Route to Gelsemine. 15. Stereoselective Construction of Oxygen Heterocycles. 16. Enantioselective Construction of Naturally-Occurring Cyclic Ethers. 17. Stereoselective Construction of Nitrogen Heterocycles. 19. The Stork Synthesis of (-)- Reserpine. 19. Stereocontrolled Construction of Azacyclic Natural Products. 20. Preparation of Benzene Derivatives. 21. Preparation of Heteroaromatics. 22. Preparation and Reactions of Carboxylic Acids, Esters and Amides. 23. The Boger Route to (-)- Vindoline. 24. Protection of C-O and C-N. 25. New Catalysts and Strategies for Alkene Metathesis. 26. Creative Applications of Alkene and Alkyne Metathesis in Total Synthesis: (+)-8epi-Xanthatin, (+)-Longicin, Latrunculin A, and Garsubellin A. 27. Synthesis of Erythronolide A. 28. Best Synthetic Methods: C-C Bond Formation. 29. Catalytic Enantioselective Homologation of Aldehydes to Alcohols and Amines. 30. Catalytic Enantioselective Construction of Alkylated Stereogenic Centers. 31. Enantioselective Construction of Arrays of Stereogenic Centers. 32. Adventures in Complex Indole Synthesis: (-)-Fixherindole I, (+)-Fischerindole G and (+)-Weltwitindolinone A. 33. New Dienes and Dienophiles for Intermolecular and Intramolecular Diels-Alder Cycloaddtions. 34. Organocatalytic Preparation of Enantiomerically-Pure Carbocycles. 35. Carbocycle Construction by the Opening of Strained Rings: Synthesis of Tremulenolide A. 36. The Corey Route to the Dolabellanes: Isoedunol and P-Araneosene. 37. Transition-Metal Catalyzed Enantioselective Ring Construction. 38. Best Synthetic Methods: Functional Group Transformation. 39. Selective Reactions of Alkenes. 40. Synthesis and Absolute Stereochemical Assignment of (-)-Galbulimima Alkaloid 13. 41. Preparation of Benzene Derivatives. 42. Preparation of Heteroaromatic Derivatives. 43. Functional Group Transformation. 44. Functional Group Protection. 45. The Leighton Synthesis of Dolabelide D. 46. Stereocontrolled Construction of N-Heterocycles. 47. Stereocontrolled Construction of O-Heterocycles. 48. Stereocontrolled Synthesis of O-Heterocyclic Natural Products. 49. The Ready Synthesis of (-)-Nigellamine A2. 50. Advances in the Diels-Alder Reaction: Synthesis of (+)-Lycoridine and of Dolabellatrienone. 51. Enantioselective Carbocyclic Construction. 52. Transition Metal Mediated Carbocyclic Construction. 53. Synthesis of (-)-Colombiasin A and (-)-Elisapterosin B. 54. Enantioselective Synthesis of C-N Ring Containing Natural Products. 55. New Catalysts and Strategies for Alkene and Alkyne Metathesis. 56. Heterocyclic Natural Products by Alkene Metathesis. 57. Carbobyclic Natural Products by Alkene Metathesis. 58. The Crimmins Synthesis of (+)-SCH 351448. 59. Enantioselective Construction of Alcohols and Amines. 60. Enantioselective Construction of Alkylated Stereogenic Centers. 61. Enantioselective Construction of Arrays of Stereogenic Centers. 62. The Sorensen Synthesis of (-)-Guanacastepene E. 63. Selective Reactions of Alkenes. 64. Best Synthetic Methods: C-C Bond Formation. 65. Functional Group Protection and Deprotection. 66. The Nicolaou Synthesis of Platensimycin. 67. Stereocontrolled C-O Ring Construction. 68. Stereocontrolled Natural Product Synthesis: Cyclic Ethers and Macrolides. 69. Stereocontrolled C-N Ring Construction. 70. Stereocontrolled Alkaloid Total Synthesis. 71. The Fukuyama Synthesis of Morphine. 73. Oxidation and Reduction in Organic Synthesis. 73. Interconversion of Organic Functional Groups. 74. Best Synthetic Methods: Carbon-Carbon Bond Formation. 75. The Overman Synthesis of (-)-Sarah A. 76. Recent Developments in Alkene Metathesis. 77. Pushing the Limits of Alkene Metathesis in Natural Product Synthesis. 78. Preparation of Benzene Derivatives. 79. The Padwa Synthesis of Aspidophytidine. 80. Synthesis of Heteroaromatics. 8 1. Enantioselective Construction of Alcohols and Amines. 82. Enantioselective Construction of Alkylated Stereogenic Centers. 83. Enantioselective Construction of Arrays of Stereogenic Centers. 84. The Gin Synthesis of Nominine. 85. The Intramolecular Diels-Alder Reaction in Natural Product Synthesis. 86. Catalytic Enantioselective Carbon-Carbon Ring Construction. 87. New Directions in C-C Ring Construction: The Overman Synthesis of Guanacastepene N. 88. The Pettus Synthesis of (+)-Rishirilide B. 89. Selective Reactions of Alkenes. 90. Selective C-H Functionalization. 91. New Methods for Carbon-Carbon Bond Formation. 92. The Nakada Synthesis of (+)-Digitoxigenin. 93. Preparation of Benzene Derivatives. 94. Preparation of Heteroaromatics: The Movassaghi Synthesis of (+)-Chimonanthine. 95. Organic Functional Group Transformation. 96. Organic Functional Group Protection. 97. The Trost Synthesis of (-)-Terpestacin. 98. Stereoselective C-N Ring Construction. 99. Stereoselective C-0 Ring Construction. 100. Synthesis of (-)-Blepharocalyxin D, (-)-Lasonolide A, and Attenol A. 101. The Dark Synthesis of Vigulariol. 102. Enantioselective Organocatalytic Synthesis of Carbocycles: The Iwabuchi Synthesis of (+)-Juvabione. 103. Transition-metal Mediated Synthesis of Carbocycles: The Snapper Synthesis of Pleocarpenone. 104. Enantioselective Construction of Carbocycles: The Williams Synthesis of (+)-Fusicoauritone. 105. C-H Functionalization: The White Reagent. Author Index. Reaction Index.

Read more less

Book SynopsisWater treatment is a growing field in North America, with seventy US states and localities and ten Canadian provinces requiring certification for water treatment plant operators. This book provides a step-by-step look at the most current water treatment technologies, balancing academic theory and professional practice.Table of ContentsPreface ix 1 Microscopic Particle Analysis 1 Bloomington Water Sources and Treatment Plant Processes 3 Number of Bacterial Cells in Natural and Treated Waters 11 Results of Microscopic Enumeration 11 Comparative Evaluation of Lime Softener/Clarifiers 14 Effect of Backwash on Filter Performance 14 Electronic Particle Counting for Evaluation of Filter Performance 18 Photomicrographs Using Epifluorescence Microscopy 19 Light Microscopy 20 References 20 2 Plant Process Evaluations 23 Particles Observed at Various Water Treatment Stages 23 Improving Filter Performance Following Backwash 26 References 32 3 Lime Softening 33 Plant Performance Evaluations 33 Removal of Organic Matter 40 Reference 40 4 Acidification Protocol 41 Regulation of Turbidity as a Microbiological Surrogate 41 Advanced Analytical Methods for Evaluation of Water Treatment Plant Performance 42 Formation of Particles During Treatment 44 Implications for Assessment of Water Treatment Plant Process Efficiency 46 Interim Enhanced Surface Water Treatment Rule 46 Acidification 47 Acidification Protocol 50 Alternate Exceedance Levels 51 References 51 5 Filter Operations 53 Particle Removal During Filtration 53 The Bloomington Filters 53 Filter Operations 57 Granular Activated Carbon Performance and Characteristics 60 Filter Media Size Distribution 64 Microbial Growth on Filter Media 68 Filter Effluent: Calcium Carbonate Post-Precipitation 70 Filter Washing 71 Procedure for Evaluating Biological Activity on Filter Media 73 Recommended Testing of Auxiliary Air Scour 73 References 74 6 Grit Removal 75 Gritting 76 ClariCone Settling Velocities Versus Applied Flow 81 Grit Removal Modification 83 Recarbonation Following Slurry Blanket Upset 85 Particle Size Analysis: Effect of Gritting 87 Post Grit 88 pH and Conductivity 89 Effect of Grit Removal on Blanket Stability 91 Revised Grit Removal Protocol 91 7 Lime Softener Performance Enhancements 95 Modified Lime Slurry Feed Points 95 Evaluation of Grit Removal Process 97 Reduction in Blanket Upsets Lime Overfeeds and Carbon Dioxide Requirements 100 Recarbonation Basins: Post-Precipitation Particle Size Analysis 100 Results of the Evaluation of the Gritting Process 102 Evaluation of the Inline Degritter 103 8 Lime Softener Operational Enhancements 107 Treatment Chemistry 108 Flow Rates to ClariCones 108 Energy Input to Impart Spiral Flow 109 Modification of Kinetic Energy Input 110 Effect of Gritting on Slurry Blanket 111 Effect of Blowdown on Sludge Blanket 112 Frequency of Intense Cleaning 112 Maintenance of Lime Delivery System 114 9 Granular Activated Carbon 117 Benefits of Granular Activated Carbon 117 Costs of Carbon 118 Reference 120 10 Plant Operations Manual 121 Development of Operations Manual and Guidelines Documents 121 Bloomington Water Supply History 121 Water Treatment Plant Processes 128 Laboratory Facilities 151 Shop Facilities 152 Operator’s Laboratory 154 Communications Between Operators and Operational Continuity 154 Future Development of Operational Guidelines 155 Reference 155 11 Taste-and-Odor Control 157 Nutrient Sources and Organism Growth 158 Laboratory Capabilities for Assessing Lake and Treated Water Quality 159 Destratification 162 Lake Source Water Protection 163 Odor Control: Operating Procedures and Processes 164 Finished Water Taste and Odor Monitoring 165 Operational Alternatives 165 Evaluation of Potential for Modified or Enhanced Treatment Process 165 Biodegradation: Bloomington’s Water Treatment Plant Operations Manual 169 Microscopic Examination and Description of Micrographs 170 Taste and Odor Remission and PAC Studies 171 Dominant Organisms in Evergreen Lake 172 Potential Future Trials 172 References 172 12 GAC Adsorption and Microbial Degradation 175 Removal of Geosmin on GAC 175 Removal of Geosmin Using Ozonated Air 181 Lake Water Monitoring for Geosmin and MIB 183 Follow-up Study of Temperature Effects 186 Ultraviolet Light plus Hydrogen Peroxide 187 Early Detection and Control of Impending Taste-and-Odor Episodes at Evergreen Lake 189 Implications for Plant Operational Control 190 Appendix A: Procedures for Total Bacterial Cell Count by Epifluorescence Microscopy 193 Appendix B: Potential Studies Involving Microscopic Particle Analysis: Particle Identification Enumeration and Sizing 199 Appendix C: Development of Operator Guidelines 203 Index 235

Read more less

Book SynopsisPharmaceutical and Biomedical Portfolio Management in a Changing Global Environment explores some of the critical forces at work today in the complex endeavour of pharmaceutical and medical product development. Written by experienced professionals, and including real-world approaches and best practice examples, this new title addresses three key areas small molecules, large molecules, and medical devices - and provides hard-to-find, consolidated information relevant to and needed by pharmaceutical, biotech, and medical device company managers.Table of ContentsFOREWORD. PREFACE. ACKNOWLEDGEMENTS. CONTRIBUTORS. ABBREVIATIONS. PART I: OVERVIEW. 1: Project Leadership for Biomedical Industries (Scott D. Babler). PART II: MANAGING MEDICAL AND PHARMACEUTICAL PROJECTS. 2: Medical Devices – Components, Systems, and their Integration (Dennis F. Marr). 3: The Role of Project Management in the Development of In Vitro Diagnostics (David Kern and Diane M. Ward). 4: Drug Development Project Management (Dirk L. Raemdonck and Bradford A. Burns). PART III: EFFECT OF BUSINESS RELATIONSHIPS ON MANAGING LARGE PROJECTS. 5: Outsourcing of Project Activities (Jonathan D. Lee and Trisha Dobson). 6: The Unique Aspects of Alliance Projects (Andrew S. Eibling). Case Study: Management of Outsourcing for Biomedical Companies (Jeffery W. Frazier, Jennifer A. Hewitt and Andy Myslicki). 7: A Roadmap for Successful Technology Transfers (Nipun Davar, Sangita Ghosh, Nandan Oza). 8: Challenges for the Team Leader of Multifunctional Product Teams in an International Environment (Hartwig Hennekes). 9: Lessons Learned from Inter-Organizational Collaboration Projects (Andrea Jahn). Case Study: Project Management in Non-Profit Drug Development (Autumn Ehnow). PART IV: MANAGING UNIQUE PROJECT COMPLEXITIES. 10: Clinical Trials and Project Management (Scott E. Smith, Carol A. Connell and Dirk L. Raemdonck). 11: Role of Project Management in Quality Planning and Functions Throughout the Product Lifecycle (Thomas Dzierozynski and Ian Fleming). 12: Regulatory Strategies and Submissions in an International Product Environment (Louise Johnson). 13: Risk Management - A Practical Approach (Courtland R. LaVallee). PART V: PORTFOLIO MANAGEMENT AND RESOURCE PLANNING. 14: Managing Successful Product Portfolio Creation and R&D Pipelines (Sue E. Steven). 15: Effective Strategies for Project Resource Planning and Utilization (Eduardo Rojas and Scott D. Babler). 16: Stage Gate Product Development Processes and Lifecycle Management (Karen E. Coulson). PART VI: TRENDS IN BMI PROJECT MANAGEMENT. 17: The Future of Medical Devices (Ronald L. Kirschner). 18: The Next Wave of Managing Biomedical Projects (Scott D. Babler). INDEX.

Read more less

Book SynopsisG protein-coupled receptors (GPCRs) are a large protein family of transmembrane receptors vital in dictating cellular responses. GPCRs are involved in many diseases, but are also the target of around half of all modern medicinal drugs. Shifting Paradigms in G Protein Coupled Receptors takes a look at the way GPCRs are examined today, how they react, how their mutations lead to disease, and the many ways in which they can be screened for compounds that modulate them. Chemists, pharmacologists, and biologists will find essential information in this comprehensive reference.Trade Review"Additionally, the presentation of the fundamental concepts of GPCR biology by the authors, who are recognized experts in the GPCR field, is likely to be appreciated by students of pharmacology. . . This is a unique resource for navigating the field of GPCR research." (Doody's, 23 September 2011) ". . . scientists whose area of research is (or will be) connected with GPCRs ... will get a comprehensive overview of current state-of-the-art research in this broad and rapidly developing field." (ChemMedChem, 1 February 2011)Table of ContentsPreface. Contributors. 1. The Evolution of Receptors: From On–Off Switches to Microprocessors (Terry Kenakin). 1.1. Introduction. 1.2. The Receptor as an On–Off Switch. 1.3. Historical Background and Classical Receptor Theory. 1.4. The Operational Model of Drug Action. 1.5. Receptor Antagonism. 1.6. Specific Models of GPCRs (7TM Receptors). 1.7. The Receptor as Microprocessor: Ternary Complex Models. 1.8. Receptors as Basic Drug Recognition Units. 1.9. Receptor Structure. 1.10. Future Considerations. References. 2. The Evolving Pharmacology of GPCRs 27 (Lauren T. May, Nicholas D. Holliday, and Stephen J. Hill). 2.1. Agonists, Neutral Antagonists, and Inverse Agonists. 2.2. LDTRS/Protean Agonism. 2.3. Molecular Mechanisms of GPCR Ligand Binding. 2.4. Two GPCR Ligands Binding at Once—Concept of Allosterism. 2.5. GPCR Dimerization. 2.6. Future Perspectives. Acknowledgments. References. 3. The Emergence of Allosteric Modulators for G Protein-Coupled Receptors (Karen J. Gregory, Celine Valant, John Simms, Patrick M. Sexton, and Arthur Christopoulos). 3.1. Introduction. 3.2. Foundations of Allosteric Receptor Theory. 3.3. Models for Understanding the Effects of Allosteric Modulators. 3.4. Types of Allosteric Modulators and Their Properties. 3.5. Detection and Quantification of Allosteric Interactions. 3.6. Some Examples of GPCR Allosteric Modulators. 3.7. Concluding Remarks. References. 4. Receptor-Mediated G Protein Activation: How, How Many, and Where? (Ingrid Gsandtner, Christian W. Gruber, and Michael Freissmuth). 4.1. The Mechanical Problem—Three Different Solutions. 4.2. Receptor Monomers–Dimers–Oligomers: One Size Fits All? 4.3. Corrals, Fences, Rafts—Are There Privileged Places for GPCR Activation? Acknowledgments. References. 5. Molecular Pharmacology of Frizzleds—with Implications for Possible Therapy (Gunnar Schulte). 5.1. Introduction. 5.2. Frizzleds as WNT Receptors. 5.3. Frizzled Signaling 120. 5.4. Frizzleds—Physiology and Possible Therapy. Acknowledgments. References. 6. Secretin Receptor Dimerization: A Possible Functionally Important Paradigm for Family B G Protein-Coupled Receptors (Kaleeckal G. Harikumar, Maoqing Dong, and Laurence J. Miller). 6.1. Methodological Approaches to GPCR Oligomerization. 6.2. Structural Themes for GPCR Oligomerization. 6.3. Functional Effects of GPCR Oligomerization. 6.4. Secretin Receptor Oligomerization. References. 7. Past and Future Strategies for GPCR Deorphanization (Angélique Levoye, Nathalie Clement, Elodie Tenconi and Ralf Jockers). 7.1. Introduction. 7.2. Current Strategies to Identify the Ligand and Function of Orphan 7TM Proteins. 7.3. Functional Assays for Deorphanization. 7.4. Future Directions and New Concepts. 7.5. Controversial Issues. Acknowledgments. References. 8. High-Throughput GPCR Screening Technologies and the Emerging Importance of the Cell Phenotype (Terry Reisine and Richard M. Eglen). 8.1. Introduction. 8.2. How Are GPCR Drugs Discovered? 8.3. GPCR Dependence on G Proteins. 8.4. Technologies for GPCR Compound Screening and Drug Discovery. 8.5. Importance of Target Cells in GPCR HTS Assays. 8.6. Summary. References. 9. Are "Traditional" Biochemical Techniques Out of Fashion in the New Era of GPCR Pharmacology? (Maria Teresa Dell’anno and Maria Rosa Mazzoni). 9.1. Overview. 9.2. Receptor Binding Assays. 9.3. Methods for Measurement of cAMP. 9.4. Conclusions. References. 10. Fluorescence and Resonance Energy Transfer Shine New Light on GPCR Function (Carsten Hoffmann and Moritz Bünemann). 10.1. Overview. 10.2. Introduction. 10.3. Labeling GPCRs with Fluorescent Tags. 10.4. Detection of Fluorescence and Bioluminescence. 10.5. Fluorescence-Based Assays to Study Receptor Localization, Trafficking and Receptor Function. 10.6. Resonance Energy Transfer, a Tool to Get New Insights into GPCR Function. 10.7. Analysis of Steady-State Protein–Protein Interaction by Means of RET. 10.8. Kinetic Analysis of Protein–Protein Interactions by Means of FRET. 10.9. Detection of Receptor Function by Fluorescence Resonance Energy. References. 11. Integration of Label-Free Detection Methods in GPCR Drug Discovery (Oliver Nayler, Magdalena Birker-Robaczewska, and John Gatfield). 11.1. Overview. 11.2. Introduction. 11.3. Label-Free Technologies—Past and Present. 11.4. Discussion. Acknowledgments. References. 12. Screening for Allosteric Modulators of G Protein-Coupled Receptors (Christopher Langmead). 12.1. Introduction. 12.2. The Allosteric Ternary Complex Model, Radioligand Binding, and Affinity. 12.3. Beyond Affinity—Functional Assays, Efficacy, and Allosteric Agonism. 12.4. Allosteric Modulator Titration Curves. 12.5. The Impact of Functional Assay Format on Allosteric Modulator Screening. 12.6. Taking Advantage of Structural Understanding of Allosteric Binding Sites. 12.7. Summary and Future Directions. References. 13. Ultra-High-Throughput Screening Assays for GPCRs (Priya Kunapuli). 13.1. Introduction. 13.2. Assay Types for GPCRs in uHTS. 13.3. Summary. Acknowledgments. References. 14. New Techniques to Express and Crystallize G Protein-Coupled Receptors (James C. Errey and Fiona H. Marshall). 14.1. Introduction. 14.2. Key Problems Limiting Production of 3D GPCR Structures. 14.3. History of GPCR Structures. 14.4. The Search for Other GPCR Structures. 14.5. Protein Purification and Solubilization. 14.6. In Cubo Crystallization. 14.7. Engineering Receptor Stability. 14.8. Structures of the â2AR. 14.9. The Adenosine A2a Receptor. 14.10. Conclusions and Future Developments. Acknowledgments. References. 15. Structure and Modeling of GPCRs: Implications for Drug Discovery (Kimberly A. Reynolds, Vsevolod Katritch, and Ruben Abagyan). 15.1. Introduction. 15.2. High-Resolution GPCR Modeling. 15.3. Constructing and Evaluating Homology Models of Other Receptor Types. 15.4. Modeling GPCR Functional Features—Analysis of Activation and Signaling. 15.5. Beyond Class A: Modeling of Other GPCR Families. 15.6. Summary and Conclusions. Acknowledgments. References. 16. X-Ray Structure Developments for GPCR Drug Targets (Michael Sabio and Sidney W. Topiol). 16.1. Overview. 16.2. Introduction. 16.3. Class A GPCRs. 16.4. Class C GPCRs. 16.5. Conclusions. References. 17. Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors (Kenneth J. Valenzano, Elfrida R. Benjamin,Patricia René, and Michel Bouvier). 17.1. Overview. 17.2. Introduction. 17.3. NDI and the V2R. 17.4. RP and the Rhodopsin Receptor. 17.5. IHH and the Gonadotropin-Releasing Hormone Receptor. 17.6. Other Human Diseases Caused by Inactivating Mutations in GPCRs. 17.7. Considerations for the Therapeutic Use of Pharmacological Chaperones. 17.8. Concluding Remarks. Acknowledgments. References. Index.

Read more less

Book SynopsisThis book conveys advances in synthetic and characterization methods in 9 selected areas of polymer chemistry reported in 2007-2008 US Patents to academic and industrial researchers and students. It reviews the impact of newer bulk anionic, cationic, and free radical polymerization methods within selected industrial applications.Table of ContentsI. ADDITIVES. II. ADHESIVES. III. BIOACTIVE. A. Bioabsorbables. B. Contact Lenses. IV. COATINGS. A. Anionic. B. Aqueous. C. Fluorine. D. Hydrophilic. E. Hydrophobic. F. Oxidatively Stable. G. Vapor Deposition of Polymers. H. Succinic Anhydride Derivatives. V. COSMETICS. VI. DENTAL. A. Cement. B. Dental Composites. VII. ELECTROACTIVE. A. Charge Transport Materials. B. Dielectric Materials. C. Donor-Acceptor Complexes. D. Electroconductive. E. Electroluminescence. F. Semiconductors. VIII. ENERGETIC POLYMERS. IX. FIBERS. X. FLUORINE. A. Critical Polymerization. B. High Strength. C. Low Molecular Wright. D. Low Surface Energy. E. Silicon Fluids. F. Surfactants. XI. GELS. A. Gelling Agent. B. Hydrogels. C. Sol-gel. XII. IMAGING AGENT. XIII. INK. XIV. LIQUID CRYSTALS. A. Liquid Crystal Aligner. B. Liquid Crystal Materials. XV. NANOPARTICLES. A. Carbon Nanotubes. B. Inorganic Nanotubes. C. Nanotube Dispersant. XVI. NEW SYNTHETIC METHODS. A. Compounds. B. Polymers. XVII. OPTICAL MATERIALS. XVIII. PHOTOACTIVE POLYMERS. A. Photoluminsence. B. Photorefraction. XIX. POLYMERIZATION METHODS. A. Anionic. B. Catalytic Agents. C. Cationic . D. Chain Transfer Agent. E. Emulsifing Agents. F. Free Radical Polymerization. G. Macroinitators. H. Macromolecular Depolymerization Catalysts. I. Metallocene Catalysts. J. Ring Opening Metathesis Catalyst. K. Ziegler-Natta. XX. REGULATORS. A. Chain Transfer Agents. B. Chain Transfer Processes. C. Photolytic Regulating Agents. XXI. PHOTORESISTS. A. Fluorine Containing. B. Norbornene. C. Adamantane. D. Diamantane. XXII. SEPARATIONS. A. Gases. B. Solutions. XXIII. THERMOSETS. Contributors. Index.

Read more less

Book SynopsisA high-volume industrial chemical used in many consumer products, methanol is poisonous at high doses and long-term exposures. This single, comprehensive source of toxicity data describes what we know about the toxic effects of methanol on humans, animals, and the environment.Table of ContentsPreface xiii Contributors xv 1 Methanol Production and Markets: Past, Present, and Future 1 Gregory A. Dolan References 9 2 Methanol: Fate and Transport in the Environment 11 Rula A. Deeb, Todd L. Anderson, Michael C. Kavanaugh, and Lauren A. Kell 2.1 Introduction 11 2.2 Partitioning of Methanol in the Environment 16 2.3 Fate and Transport of Methanol in the Environment 22 2.4 Methanol Additives 37 2.5 Conclusions 40 References 40 3 Human Toxicity 47 John J. Clary 3.1 Introduction 47 3.2 Exposure 48 3.3 Metabolism in Humans 50 3.4 History of Human Toxicity 54 3.5 Controlled Human Studies 60 3.6 In Utero Exposure 62 3.7 Repeat Inhalation Exposure 63 3.8 Management of Methanol Poisoning 64 3.9 Conclusions 66 References 67 4 General Animal and Aquatic Toxicity 73 John J. Clary 4.1 Introduction 73 4.2 Acute Toxicity 74 4.3 Irritation 86 4.4 Sensitization 87 4.5 Repeat Exposure—Inhalation 87 4.6 Repeat Exposure—Oral 94 4.7 Repeat Exposure—Dermal 96 4.8 Aquatic Toxicity 96 4.9 Conclusion 99 References 100 5 Developmental and Reproductive Toxicology of Methanol 107 John M. Rogers, Jeffrey S. Gift, and Stanley Barone, Jr. 5.1 Introduction 107 5.2 Reproductive Toxicity 108 5.3 Developmental Toxicity 110 5.4 Conclusions 136 Disclaimer 139 References 139 6 Exploring Differences Between PBPK Models of Methanol Disposition in Mice and Humans: Important Lessons Learned 145 Thomas B. Starr 6.1 Background 145 6.2 Are Humans More or Less Sensitive than Mice to the Toxic Effects of Methanol? 148 6.3 Are the Two Models’ Predictions of Human Blood Methanol Concentrations at Steady State Consistent with Each Other? 153 6.4 Are the Values of Key Human Metabolism Parameters Consistent with Those in the Published Scientific Literature? 155 6.5 Shouldn’t the Possibility of Systematic Bias be Considered Carefully During the Model Fitting and Parameter Estimation Process? 160 6.6 Is “Visual Optimization” an Adequate Technique for Estimating PBPK Model Parameters? 161 6.7 When Human Data are Available, Shouldn’t they be Utilized in Making an Objective Comparison of Model-Specific Predictions? 163 6.8 Summary of Lessons Learned 164 References 165 7 Oxidative Stress and Species Differences in the Metabolism, Developmental Toxicity, and Carcinogenic Potential of Methanol and Ethanol 169 Peter G. Wells, Gordon P. McCallum, Lutfiya Miller, Michelle Siu, and J. Nicole Sweeting 7.1 Introduction 169 7.2 Species Differences in Methanol Metabolism 179 7.3 Species and Strain Differences in Methanol Toxicity 191 7.4 Oxidative Stress 213 7.5 Conclusions 237 Acknowledgment 238 References 238 8 Methanol and Cancer 255 John J. Clary 8.1 Introduction 255 8.2 Rodent Bioassay 256 8.3 Possible Mechanisms 270 8.4 Human Cancer Data 276 8.5 Conclusion 276 References 277 Index 283

Read more less

Book Synopsis* Covering a wide range of receptors and molecular targets, this book provides a comprehensive resource for neuro-drug discovery and molecular targets for schizophrenia.Trade Review“In summary, this book provides a timely and convenient reflection on schizophrenia drug discovery and development, which has been a major component of psychiatric drug research for several decades.” (ChemMedChem, 1 March 2013) Table of ContentsPreface vii Contributors xi Introduction 1 Alan J. Cross 1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5 Aurelija Jucaite and Svante Nyberg 2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37 Philip G. Strange 3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51 Kevin N. Boyd and Richard B. Mailman 4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85 Judith A. Siuciak and William J. Pitts 5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115 Joseph T. Coyle, Alo Basu, and Michael Benneyworth 6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143 Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn 7 AMPA Receptor Positive Modulators 187 John A. Morrow, John K.F. Maclean, and Craig Jamieson 8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233 Jeffrey S. Albert and Michael W. Wood 9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255 Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones 10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273 Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis 11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295 Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic 12 α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319 Mihály Hajós and Bruce N. Rogers 13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355 Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu 14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381 Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson 15 GABA and Schizophrenia 425 John H. Kehne and George D. Maynard Index 469

Read more less

Book SynopsisMETABOLIC SYNDROME A comprehensive look at the fight against the metabolic syndrome epidemic Increasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. Metabolic Syndrome: Underlying Mechanisms and Drug therapies extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of molecular mechanisms and drug pharmacology for pharmaceutical scientists. The book starts by examining the physiology of metabolic tissues under normal and disease states, followed by discussions of metabolic diseases and clinical complications. The development of drug therapies based on emerging science is then covered extensively. In addition, there is an in-depth look into the metabolic pathways and dysfunctions in metabolic disease, especially type 2 diabetes and lipid disorders. Finally, a chapter is devoted to past succTrade Review"This is an outstanding addition to the current body of work on the metabolic syndrome. I thought it particularly exhaustive in its review of the literature, making it an excellent resource for scouring the primary literature, and found the duality of current and future treatment approaches particularly insightful." (Doody's, 21 October 2011) "The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications." (Pharmiweb, 1 March 2011)Table of ContentsIntroduction ix Minghan Wang Contributors xi Part One The Physiology of Metabolic Tissues Under Normal and Disease States 1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3 Minghan Wang 2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29 Lourdes Mounien and Bernard Thorens 3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53 Taly Meas and Pierre-Jean Guillausseau 4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73 Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka 5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133 Ruojing Yang 6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157 Minghan Wang Part Two Metabolic Diseases and Current Therapies 7. Mechanisms and Complications of Metabolic Syndrome 179 Minghan Wang 8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199 Margrit Schwarz and Jae B. Kim 9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235 Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap 10. Current Antidiabetic Therapies and Mechanisms 253 Minghan Wang Part Three Drug Targets for Antidiabetic Therapies 11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281 Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy 12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327 C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth 13. Sodium Glucose Cotransporter 2 Inhibitors 359 Margaret Ryan and Serge A. Jabbour 14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377 Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov 15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391 Qiang Tong 16. 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423 Clarence Hale and David J. St. Jean, Jr. 17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459 Hai Yan, Wei Gu, and Murielle Veniant-Ellison Part Four Lessons Learned and Future Outlook 18. Drug Development for Metabolic Diseases: Past, Present and Future 471 Minghan Wang Index 489

Read more less

Book SynopsisPosttraumatic Growth and Culturally Competent Practice: Lessons Learned from Around the Globe brings welcome attention to applying PTG to culturally competent practice worldwide. It delivers on the promise embedded in its title: lots of lessons within the fourteen chapters. ?From the Foreword by Charles R. Figley, PhD, Kurzweg Chair in Disaster Mental Health, Tulane University, New Orleans The latest advances in the theoretical, empirical, and clinical aspects of Posttraumatic Growth Posttraumatic Growth and Culturally Competent Practice offers contributions from an international group of experts in posttraumatic growth (PTG) within diverse cultures and subcultures. It uniquely illuminates the nature, meaning, and clinical implications of PTG across a wide range of sociocultural contexts. Edited by Tzipi Weiss and Roni Berger?recognized experts in the areas of stress, coping, and PTG?this book features contributions by an international panelTable of ContentsForeword, ix About the Editors, xi About the Contributors, xiii Acknowledgements, xix Introduction, xxi Chapter 1 The Posttraumatic Growth Model: Sociocultural Considerations, 1Lawrence G. Calhoun, Arnie Cann, and Richard G. Tedeschi Chapter 2 Posttraumatic Growth in Israeli Jews, 15Avital Laufer and Zahava Solomon Chapter 3 Posttraumatic Growth in Middle Eastern Context: Expression and determinants among Palestinians, 31Raija-Leena Punamäki Chapter 4 Posttraumatic Growth in the Turkish Population, 49Cengiz Kiliç Chapter 5 Thriving in Postwar Kosova, 65Aliriza Arënliu and Moshe S. Landsman Chapter 6 Trauma and Posttraumatic Growth in Germany, 73BirgitWagner and Andreas Maercker Chapter 7 Posttraumatic Growth in the Netherlands, 85Grieteke Pool, Mirjam J. Nijdam, & Marijke E. Oostingh Chapter 8 Posttraumatic Growth in Spain, 97Carmelo Vázquez and Darío Páez Chapter 9 Posttraumatic Growth in U.S. Latinos, 113Roni Berger and Tzipi Weiss Chapter 10 Posttraumatic Growth in Japan: A Path toward Better Understanding of Culture-Constant and Culture-Specific Aspects, 129Kanako Taku Chapter 11 Posttraumatic Growth in Chinese Culture, 147Samuel M. Y. Ho and Yu Bai Chapter 12 Posttraumatic Growth in Australian Populations, 157Jane Shakespeare-Finch and Bronwyn Morris Chapter 13 Posttraumatic Growth in International Study: The Case of Chinese in Australia, 173Thomas A. Whelan and Winifred A. Cunningham Chapter 14 Posttraumatic Growth Around the Globe: Research Findings and Practice Implications, 189Tzipi Weiss and Roni Berger Author Index, 197 Subject Index, 207

Read more less

Book SynopsisThe high-stakes process of submitting drug documents and applications for regulatory review can be intimidating, particularly for the inexperienced regulatory professional charged with preparing a major regulatory submission.Trade Review“The Guidebook for Drug Regulatory Submissions offers a readable and clearly written road map for effective submission of documents for required regulatory reviews during drug development.” (Pharmaceutical Outsourcing, April 2009)Table of ContentsPreface ix Chapter 1 Ten Rules for Drug Regulatory Submissions 1 Chapter 2 FDA Meeting Requests 44 Chapter 3 Orphan-Drug Applications 64 Chapter 4 Investigational New Drug Applications (INDs) 82 Chapter 5 New Drug Applications (NDAs) 120 Chapter 6 505(b)2 New Drug Applications (NDAs) 183 Chapter 7 Abbreviated New Drug Applications (ANDAs) 255 Chapter 8 Annual Reports 288 Chapter 9 International Regulatory Submissions 315Carl A. Rockburne Chapter 10 Future Issues in Regulatory Submissions 355 Index 367

Read more less